https://trial.medpath.com/news/verve-therapeutics-announces-anticipated-2025-milestones-for-gene-editing-programs 2025-01-13T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verve-therapeutics-announces-anticipated-2025-milestones-for-gene-editing-programs 2025-01-13T12:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-neurological-biomarkers-market-set-to-triple-to-31-82-billion-by-2034 2025-01-13T12:38:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-neurological-biomarkers-market-set-to-triple-to-31-82-billion-by-2034 2025-01-13T12:38:46+00:00 hourly 0.9 https://trial.medpath.com/news/icecure-medical-reports-42-increase-in-prosense-sales-for-2024-in-north-america 2025-01-13T12:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icecure-medical-reports-42-increase-in-prosense-sales-for-2024-in-north-america 2025-01-13T12:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/x4-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement 2025-01-13T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x4-pharmaceuticals-and-norgine-enter-into-exclusive-licensing-agreement 2025-01-13T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/voyageur-begins-human-testing-for-innovative-barium-contrast-product-line 2025-01-13T12:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyageur-begins-human-testing-for-innovative-barium-contrast-product-line 2025-01-13T12:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/verastem-oncology-announces-debt-refinancing-and-equity-investment 2025-01-13T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verastem-oncology-announces-debt-refinancing-and-equity-investment 2025-01-13T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/foghorn-therapeutics-advances-in-cancer-treatment-with-innovative-programs 2025-01-13T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foghorn-therapeutics-advances-in-cancer-treatment-with-innovative-programs 2025-01-13T12:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-pharmaceuticals-highlights-key-achievements-and-future-milestones-at-j-p-morgan-healthcare-conference 2025-01-13T12:23:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syndax-pharmaceuticals-highlights-key-achievements-and-future-milestones-at-j-p-morgan-healthcare-conference 2025-01-13T12:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-transplants-may-help-people-who-have-diabetes-gut-issues-study-says 2025-01-13T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-transplants-may-help-people-who-have-diabetes-gut-issues-study-says 2025-01-13T12:22:16+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-announces-2025-development-milestones-and-company-updates 2025-01-13T12:22:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-announces-2025-development-milestones-and-company-updates 2025-01-13T12:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/cartesian-therapeutics-advances-mrna-cell-therapies-for-autoimmune-diseases 2025-01-13T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cartesian-therapeutics-advances-mrna-cell-therapies-for-autoimmune-diseases 2025-01-13T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/eledon-pharmaceuticals-achieves-key-milestones-and-sets-2025-goals 2025-01-13T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eledon-pharmaceuticals-achieves-key-milestones-and-sets-2025-goals 2025-01-13T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/fractyl-health-announces-positive-initial-clinical-results-for-weight-maintenance-post-glp-1-discontinuation 2025-01-13T12:15:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fractyl-health-announces-positive-initial-clinical-results-for-weight-maintenance-post-glp-1-discontinuation 2025-01-13T12:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-deep-brain-stimulation-enhances-mental-flexibility-in-mental-illness 2025-01-13T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-deep-brain-stimulation-enhances-mental-flexibility-in-mental-illness 2025-01-13T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/bicycle-therapeutics-cancer-drug-shows-impressive-65-response-rate-in-phase-1-trial 2025-01-13T12:09:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicycle-therapeutics-cancer-drug-shows-impressive-65-response-rate-in-phase-1-trial 2025-01-13T12:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-expands-flamingo-01-trial-into-france-with-unicancer-partnership 2025-01-13T12:09:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-expands-flamingo-01-trial-into-france-with-unicancer-partnership 2025-01-13T12:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-outlines-key-2025-objectives-and-business-update 2025-01-13T12:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-therapeutics-outlines-key-2025-objectives-and-business-update 2025-01-13T12:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/normunity-secures-75-million-series-b-financing-to-propel-cancer-therapy-development 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/normunity-secures-75-million-series-b-financing-to-propel-cancer-therapy-development 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-libtayo-cemiplimab-shows-significant-improvement-in-disease-free-survival-for-high-risk-cscc-patients 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-libtayo-cemiplimab-shows-significant-improvement-in-disease-free-survival-for-high-risk-cscc-patients 2025-01-13T12:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/elicera-therapeutics-drug-candidate-elc-100-receives-orphan-drug-designation-in-the-u-s 2025-01-13T12:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elicera-therapeutics-drug-candidate-elc-100-receives-orphan-drug-designation-in-the-u-s 2025-01-13T12:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-nci-sponsored-clinical-trial-of-iadademstat-combination-for-aml 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-nci-sponsored-clinical-trial-of-iadademstat-combination-for-aml 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-advances-sickle-cell-treatment-and-genetic-disease-therapies 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-advances-sickle-cell-treatment-and-genetic-disease-therapies 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-biosciences-showcases-nanosecond-pfa-technology-at-af-symposium-2025 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulse-biosciences-showcases-nanosecond-pfa-technology-at-af-symposium-2025 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-advances-in-pharmaceutical-r-d-with-strategic-collaborations-and-clinical-trials 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-advances-in-pharmaceutical-r-d-with-strategic-collaborations-and-clinical-trials 2025-01-13T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-aims-for-first-potential-approval-in-2026-with-new-cancer-treatments 2025-01-13T11:39:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-aims-for-first-potential-approval-in-2026-with-new-cancer-treatments 2025-01-13T11:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-to-acquire-intra-cellular-therapies-strengthening-neuroscience-leadership 2025-01-13T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-to-acquire-intra-cellular-therapies-strengthening-neuroscience-leadership 2025-01-13T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/positive-outlook-for-tyra-bioscience-following-fda-clearance-and-promising-clinical-data 2025-01-13T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-outlook-for-tyra-bioscience-following-fda-clearance-and-promising-clinical-data 2025-01-13T11:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/regor-s-obesity-pill-shows-modest-weight-loss-in-phase-2a-advances-to-new-trial 2025-01-13T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regor-s-obesity-pill-shows-modest-weight-loss-in-phase-2a-advances-to-new-trial 2025-01-13T11:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-holdings-invests-in-windward-bio-for-immunological-disease-treatments 2025-01-13T11:07:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-holdings-invests-in-windward-bio-for-immunological-disease-treatments 2025-01-13T11:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-and-gene-therapy-breakthroughs-advance-treatment-options-for-parkinson-s-and-amd 2025-01-13T10:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-and-gene-therapy-breakthroughs-advance-treatment-options-for-parkinson-s-and-amd 2025-01-13T10:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-completes-subject-randomisation-in-phase-iib-mdd-treatment-trial 2025-01-13T10:56:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmnc-completes-subject-randomisation-in-phase-iib-mdd-treatment-trial 2025-01-13T10:56:03+00:00 hourly 0.9 https://trial.medpath.com/news/efficacy-and-safety-of-bi-1358894-in-patients-with-borderline-personality-disorder 2025-01-13T10:35:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efficacy-and-safety-of-bi-1358894-in-patients-with-borderline-personality-disorder 2025-01-13T10:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-advances-into-cohort-7-in-phase-i-iia-study-for-multiple-myeloma-treatment 2025-01-13T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-advances-into-cohort-7-in-phase-i-iia-study-for-multiple-myeloma-treatment 2025-01-13T10:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/distinct-mechanisms-of-her2-targeting-agents-in-nsclc-understanding-tkis-vs-adcs 2025-01-13T09:56:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/distinct-mechanisms-of-her2-targeting-agents-in-nsclc-understanding-tkis-vs-adcs 2025-01-13T09:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/oric-944-shows-promising-psa-response-in-advanced-prostate-cancer-combination-study 2025-01-13T09:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oric-944-shows-promising-psa-response-in-advanced-prostate-cancer-combination-study 2025-01-13T09:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-gains-approval-for-new-diabetes-drug 2025-01-13T09:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-gains-approval-for-new-diabetes-drug 2025-01-13T09:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/summit-s-ivonescimab-emerges-as-potential-keytruda-challenger-in-major-cancer-treatment-breakthrough 2025-01-13T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-s-ivonescimab-emerges-as-potential-keytruda-challenger-in-major-cancer-treatment-breakthrough 2025-01-13T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-smoking-cessation-program-shows-superior-results-in-lung-cancer-screening-setting 2025-01-13T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-smoking-cessation-program-shows-superior-results-in-lung-cancer-screening-setting 2025-01-13T09:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionizing-drug-development-the-rise-of-targeted-protein-degradation 2025-01-13T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionizing-drug-development-the-rise-of-targeted-protein-degradation 2025-01-13T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-bluerock-advances-parkinson-s-cell-therapy-to-phase-iii 2025-01-13T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-bluerock-advances-parkinson-s-cell-therapy-to-phase-iii 2025-01-13T09:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-and-challenges-in-clinical-trials-a-2024-overview 2025-01-13T09:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-and-challenges-in-clinical-trials-a-2024-overview 2025-01-13T09:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/eckert-ziegler-and-glytherix-expand-collaboration-with-actinium-225-supply-agreement 2025-01-13T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eckert-ziegler-and-glytherix-expand-collaboration-with-actinium-225-supply-agreement 2025-01-13T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/scitech-development-advances-st-001-nanofenretinide-to-next-clinical-trial-phase-for-t-cell-lymphoma 2025-01-13T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scitech-development-advances-st-001-nanofenretinide-to-next-clinical-trial-phase-for-t-cell-lymphoma 2025-01-13T09:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/spear-bio-s-ptau-217-blood-test-receives-fda-breakthrough-device-designation-for-early-alzheimer-s-diagnosis 2025-01-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spear-bio-s-ptau-217-blood-test-receives-fda-breakthrough-device-designation-for-early-alzheimer-s-diagnosis 2025-01-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fractyl-health-s-revita-procedure-shows-promise-in-sustained-weight-loss-management 2025-01-13T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fractyl-health-s-revita-procedure-shows-promise-in-sustained-weight-loss-management 2025-01-13T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-ethnic-disparities-in-early-onset-colorectal-cancer-diagnoses-across-nhs 2025-01-13T08:43:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-ethnic-disparities-in-early-onset-colorectal-cancer-diagnoses-across-nhs 2025-01-13T08:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/novel-ctdna-blood-test-shows-promise-in-predicting-lung-cancer-treatment-outcomes 2025-01-13T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-ctdna-blood-test-shows-promise-in-predicting-lung-cancer-treatment-outcomes 2025-01-13T08:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/silent-progression-of-glaucoma-expert-highlights-critical-need-for-early-detection 2025-01-13T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silent-progression-of-glaucoma-expert-highlights-critical-need-for-early-detection 2025-01-13T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/hvivo-plc-completes-pilot-hmpv-characterisation-study 2025-01-13T08:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hvivo-plc-completes-pilot-hmpv-characterisation-study 2025-01-13T08:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-to-unveil-sil-204-data-for-kras-driven-pancreatic-cancer-at-2025-asco-gi-cancers-symposium 2025-01-13T07:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silexion-therapeutics-to-unveil-sil-204-data-for-kras-driven-pancreatic-cancer-at-2025-asco-gi-cancers-symposium 2025-01-13T07:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/walden-biosciences-announces-2024-achievements-and-2025-goals 2025-01-13T07:44:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walden-biosciences-announces-2024-achievements-and-2025-goals 2025-01-13T07:44:49+00:00 hourly 0.9 https://trial.medpath.com/news/telehealth-proves-equally-effective-as-in-person-visits-for-asthma-management-study-shows 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telehealth-proves-equally-effective-as-in-person-visits-for-asthma-management-study-shows 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/elevation-oncology-advances-clinical-trials-for-gastric-gej-cancer-treatment 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevation-oncology-advances-clinical-trials-for-gastric-gej-cancer-treatment 2025-01-13T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-to-acquire-idrx-inc-in-a-deal-worth-up-to-1-15-billion 2025-01-13T07:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-to-acquire-idrx-inc-in-a-deal-worth-up-to-1-15-billion 2025-01-13T07:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-data-science-set-to-transform-life-sciences-industry-by-2025 2025-01-13T07:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-data-science-set-to-transform-life-sciences-industry-by-2025 2025-01-13T07:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-sets-strategic-goals-for-2025-with-focus-on-gene-based-medicine-and-clinical-trials 2025-01-13T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-sets-strategic-goals-for-2025-with-focus-on-gene-based-medicine-and-clinical-trials 2025-01-13T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-new-test-for-b-cell-lymphoma-obtains-fda-clearance 2025-01-13T06:27:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-new-test-for-b-cell-lymphoma-obtains-fda-clearance 2025-01-13T06:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/khyber-medical-university-to-conduct-clinical-trials-for-new-leishmaniasis-drug 2025-01-13T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/khyber-medical-university-to-conduct-clinical-trials-for-new-leishmaniasis-drug 2025-01-13T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/idh1-targeted-therapy-shows-promise-in-improving-mds-patient-outcomes-ash-2024-data-reveals 2025-01-13T06:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idh1-targeted-therapy-shows-promise-in-improving-mds-patient-outcomes-ash-2024-data-reveals 2025-01-13T06:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-novel-cancer-drug-int230-6-shows-promise-in-advanced-sarcoma-and-breast-cancer 2025-01-13T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-novel-cancer-drug-int230-6-shows-promise-in-advanced-sarcoma-and-breast-cancer 2025-01-13T06:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/scandion-oncology-announces-final-data-from-the-corist-trial 2025-01-13T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scandion-oncology-announces-final-data-from-the-corist-trial 2025-01-13T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-leads-320m-investment-in-truveta-for-massive-genome-database-project 2025-01-13T06:00:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-leads-320m-investment-in-truveta-for-massive-genome-database-project 2025-01-13T06:00:25+00:00 hourly 0.9 https://trial.medpath.com/news/rion-completes-enrollment-for-phase-2-clinical-study-of-peptm-in-diabetic-foot-ulcers 2025-01-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rion-completes-enrollment-for-phase-2-clinical-study-of-peptm-in-diabetic-foot-ulcers 2025-01-13T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d-150-gene-therapy-shows-promising-results-in-diabetic-macular-edema-trial 2025-01-13T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4d-150-gene-therapy-shows-promising-results-in-diabetic-macular-edema-trial 2025-01-13T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/extended-ambulation-period-correlates-with-improved-cardiac-function-in-adult-dmd-patients 2025-01-13T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-ambulation-period-correlates-with-improved-cardiac-function-in-adult-dmd-patients 2025-01-13T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hepcidin-mimetic-and-interferons-reshape-polycythemia-vera-treatment-landscape 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hepcidin-mimetic-and-interferons-reshape-polycythemia-vera-treatment-landscape 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nvidia-expands-healthcare-ai-footprint-with-iqvia-illumina-and-mayo-clinic-partnerships 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nvidia-expands-healthcare-ai-footprint-with-iqvia-illumina-and-mayo-clinic-partnerships 2025-01-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jpm-healthcare-conference-2025-industry-leaders-to-converge-in-san-francisco-for-landmark-biotech-event 2025-01-13T04:40:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jpm-healthcare-conference-2025-industry-leaders-to-converge-in-san-francisco-for-landmark-biotech-event 2025-01-13T04:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/mereo-biopharma-s-setrusumab-shows-promise-in-phase-ii-alvelestat-gains-ema-orphan-status 2025-01-13T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mereo-biopharma-s-setrusumab-shows-promise-in-phase-ii-alvelestat-gains-ema-orphan-status 2025-01-13T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/olix-pharmaceuticals-confirms-safety-and-tolerability-of-hair-loss-drug-in-australian-phase-1-study 2025-01-13T03:44:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olix-pharmaceuticals-confirms-safety-and-tolerability-of-hair-loss-drug-in-australian-phase-1-study 2025-01-13T03:44:09+00:00 hourly 0.9 https://trial.medpath.com/news/kmu-to-conduct-clinical-trials-of-new-leishmaniasis-drug 2025-01-13T02:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kmu-to-conduct-clinical-trials-of-new-leishmaniasis-drug 2025-01-13T02:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-highlights-2025-corporate-strategy-and-business-priorities 2025-01-13T02:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-highlights-2025-corporate-strategy-and-business-priorities 2025-01-13T02:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-innovations-in-regenerative-medicine-target-parkinson-s-heart-disease-and-amd 2025-01-13T01:58:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-innovations-in-regenerative-medicine-target-parkinson-s-heart-disease-and-amd 2025-01-13T01:58:09+00:00 hourly 0.9 https://trial.medpath.com/news/tune-therapeutics-secures-175m-for-hepatitis-b-treatment-and-epigenetic-research 2025-01-13T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tune-therapeutics-secures-175m-for-hepatitis-b-treatment-and-epigenetic-research 2025-01-13T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/eversana-transforms-pharmaceutical-commercialization-with-integrated-launch-model 2025-01-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eversana-transforms-pharmaceutical-commercialization-with-integrated-launch-model 2025-01-13T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/socazolimab-shows-promise-in-treating-extensive-stage-small-cell-lung-cancer 2025-01-13T00:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/socazolimab-shows-promise-in-treating-extensive-stage-small-cell-lung-cancer 2025-01-13T00:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-initiates-cb-010-gallop-phase-1-trial-in-lupus 2025-01-13T00:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-initiates-cb-010-gallop-phase-1-trial-in-lupus 2025-01-13T00:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-drug-durvalumab-shows-promise-in-increasing-survival-rates-for-bladder-cancer-patients 2025-01-13T00:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-drug-durvalumab-shows-promise-in-increasing-survival-rates-for-bladder-cancer-patients 2025-01-13T00:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-achieves-ce-mark-approval-for-brainsensetm-adaptive-deep-brain-stimulation 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-achieves-ce-mark-approval-for-brainsensetm-adaptive-deep-brain-stimulation 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/editas-medicine-advances-in-gene-editing-with-new-preclinical-data-and-strategic-priorities 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/editas-medicine-advances-in-gene-editing-with-new-preclinical-data-and-strategic-priorities 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-explores-first-line-use-of-kras-inhibitor-lumakras-in-nsclc-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-explores-first-line-use-of-kras-inhibitor-lumakras-in-nsclc-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-biotherapeutics-partners-with-brainomix-to-leverage-ai-in-lung-fibrosis-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridge-biotherapeutics-partners-with-brainomix-to-leverage-ai-in-lung-fibrosis-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-skyrizi-r-risankizumab-now-available-on-nhs-scotland-for-ulcerative-colitis-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-skyrizi-r-risankizumab-now-available-on-nhs-scotland-for-ulcerative-colitis-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-confirms-metformin-s-safety-profile-matches-insulin-for-diabetes-management-during-pregnancy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-confirms-metformin-s-safety-profile-matches-insulin-for-diabetes-management-during-pregnancy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nurix-therapeutics-sets-ambitious-2025-goals-for-cancer-and-autoimmune-disease-treatments 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nurix-therapeutics-sets-ambitious-2025-goals-for-cancer-and-autoimmune-disease-treatments 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-hipec-does-not-improve-outcomes-for-recurrent-epithelial-ovarian-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-hipec-does-not-improve-outcomes-for-recurrent-epithelial-ovarian-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-launches-phase-3-trial-for-covid-19-influenza-combination-vaccine 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-launches-phase-3-trial-for-covid-19-influenza-combination-vaccine 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/libtayo-cemiplimab-shows-promising-results-in-advanced-skin-cancer-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/libtayo-cemiplimab-shows-promising-results-in-advanced-skin-cancer-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cmu-and-healthcare-system-secures-unprecedented-17-awards-at-the-2024-taiwan-national-innovation-awards 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cmu-and-healthcare-system-secures-unprecedented-17-awards-at-the-2024-taiwan-national-innovation-awards 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-177-psma-radioligand-therapy-shows-promising-results-in-early-line-treatment-of-metastatic-castration-resistant-prostate-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutetium-177-psma-radioligand-therapy-shows-promising-results-in-early-line-treatment-of-metastatic-castration-resistant-prostate-cancer 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-initiates-national-coverage-analysis-for-medtronic-s-renal-denervation-system 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-initiates-national-coverage-analysis-for-medtronic-s-renal-denervation-system 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-seeks-earlier-line-use-of-breyanzi-in-lymphoma-following-trial-success 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-seeks-earlier-line-use-of-breyanzi-in-lymphoma-following-trial-success 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/smartphone-app-enhances-knowledge-and-symptom-management-for-rcc-patients-on-ici-tki-therapy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartphone-app-enhances-knowledge-and-symptom-management-for-rcc-patients-on-ici-tki-therapy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-achieves-first-50-million-milestone-in-sanofi-partnership-advancing-covid-19-and-influenza-vaccine-development 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-achieves-first-50-million-milestone-in-sanofi-partnership-advancing-covid-19-and-influenza-vaccine-development 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-advances-in-cancer-treatment-research 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-advances-in-cancer-treatment-research 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-a-s-announces-key-updates-and-achievements-in-2024 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-a-s-announces-key-updates-and-achievements-in-2024 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapy-of-ibrutinib-and-rituximab-shows-promise-in-treating-cgvhd 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapy-of-ibrutinib-and-rituximab-shows-promise-in-treating-cgvhd 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-on-diacylglycerol-edible-oil-s-impact-on-chronic-metabolic-syndrome-patients-with-hyperuricemia 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-on-diacylglycerol-edible-oil-s-impact-on-chronic-metabolic-syndrome-patients-with-hyperuricemia 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-of-neurosigma-s-monarch-etns-system-for-adhd-completes-enrollment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-of-neurosigma-s-monarch-etns-system-for-adhd-completes-enrollment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-advances-in-phase-1-clinical-trial-for-ttx-mc138-a-novel-rna-oncology-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-advances-in-phase-1-clinical-trial-for-ttx-mc138-a-novel-rna-oncology-treatment 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-halts-development-of-eliapixant-due-to-safety-concerns 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-halts-development-of-eliapixant-due-to-safety-concerns 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-study-confirms-metformin-s-safety-profile-matches-insulin-for-diabetes-management-during-pregnancy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-study-confirms-metformin-s-safety-profile-matches-insulin-for-diabetes-management-during-pregnancy 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-blood-test-shows-71-accuracy-in-detecting-pancreatic-cancer-advancing-toward-clinical-use 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-blood-test-shows-71-accuracy-in-detecting-pancreatic-cancer-advancing-toward-clinical-use 2025-01-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actinogen-s-lead-drug-xanamem-gains-who-recognition-amid-ongoing-trials 2025-01-12T23:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinogen-s-lead-drug-xanamem-gains-who-recognition-amid-ongoing-trials 2025-01-12T23:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-inc-vrtx-announces-significant-program-updates-ahead-of-2025 2025-01-12T23:15:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-inc-vrtx-announces-significant-program-updates-ahead-of-2025 2025-01-12T23:15:05+00:00 hourly 0.9 https://trial.medpath.com/news/xilio-therapeutics-strengthens-leadership-team-with-new-chief-legal-officer-amid-advancement-of-tumor-activated-immunotherapy-pipeline 2025-01-12T23:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xilio-therapeutics-strengthens-leadership-team-with-new-chief-legal-officer-amid-advancement-of-tumor-activated-immunotherapy-pipeline 2025-01-12T23:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-to-showcase-2025-strategic-initiatives-and-clinical-advancements-at-biotech-showcase 2025-01-12T23:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-to-showcase-2025-strategic-initiatives-and-clinical-advancements-at-biotech-showcase 2025-01-12T23:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/cingulate-stock-rated-buy-by-roth-mkm-anticipates-1-6b-sales-potential 2025-01-12T22:19:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cingulate-stock-rated-buy-by-roth-mkm-anticipates-1-6b-sales-potential 2025-01-12T22:19:21+00:00 hourly 0.9 https://trial.medpath.com/news/reviva-pharmaceuticals-stock-rated-buy-by-roth-mkm-backed-by-phase-3-results 2025-01-12T22:19:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reviva-pharmaceuticals-stock-rated-buy-by-roth-mkm-backed-by-phase-3-results 2025-01-12T22:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/blueprint-medicines-provides-2025-outlook-and-highlights-strategy-for-continued-growth 2025-01-12T21:42:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blueprint-medicines-provides-2025-outlook-and-highlights-strategy-for-continued-growth 2025-01-12T21:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-receives-buy-rating-due-to-strong-pipeline-and-financial-health 2025-01-12T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-receives-buy-rating-due-to-strong-pipeline-and-financial-health 2025-01-12T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-reports-strong-33-growth-sets-ambitious-2-25b-revenue-target-for-2025 2025-01-12T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-reports-strong-33-growth-sets-ambitious-2-25b-revenue-target-for-2025 2025-01-12T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-complexity-and-supply-chain-challenges-shape-apac-clinical-services-landscape 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulatory-complexity-and-supply-chain-challenges-shape-apac-clinical-services-landscape 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results-and-2025-outlook 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-announces-preliminary-fourth-quarter-and-full-year-2024-financial-results-and-2025-outlook 2025-01-12T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geode-capital-management-llc-increases-stake-in-maia-biotechnology-inc 2025-01-12T20:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geode-capital-management-llc-increases-stake-in-maia-biotechnology-inc 2025-01-12T20:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-announces-strategic-updates-at-jp-morgan-healthcare-conference 2025-01-12T18:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-announces-strategic-updates-at-jp-morgan-healthcare-conference 2025-01-12T18:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-partners-announces-clinical-expansion-and-radiopharma-strategy-at-j-p-morgan-healthcare-conference 2025-01-12T18:25:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-partners-announces-clinical-expansion-and-radiopharma-strategy-at-j-p-morgan-healthcare-conference 2025-01-12T18:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-announces-preliminary-2024-revenue-and-2025-financial-guidance-along-with-pipeline-updates 2025-01-12T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-announces-preliminary-2024-revenue-and-2025-financial-guidance-along-with-pipeline-updates 2025-01-12T16:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/leyden-labs-secures-70-million-to-advance-intranasal-antibody-programs 2025-01-12T15:42:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leyden-labs-secures-70-million-to-advance-intranasal-antibody-programs 2025-01-12T15:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/bacteriophages-a-potential-ally-against-superbugs 2025-01-12T15:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bacteriophages-a-potential-ally-against-superbugs 2025-01-12T15:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/curevo-announces-positive-updated-phase-2-data-for-amezosvatein-shingles-vaccine 2025-01-12T15:17:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevo-announces-positive-updated-phase-2-data-for-amezosvatein-shingles-vaccine 2025-01-12T15:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/secukinumab-demonstrates-long-term-efficacy-and-safety-in-treating-pediatric-gpp 2025-01-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secukinumab-demonstrates-long-term-efficacy-and-safety-in-treating-pediatric-gpp 2025-01-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-partners-and-orano-med-expand-partnership-for-cancer-therapy-development 2025-01-12T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-partners-and-orano-med-expand-partnership-for-cancer-therapy-development 2025-01-12T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requires-label-update-for-agios-pharmaceuticals-pyrukynd 2025-01-12T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requires-label-update-for-agios-pharmaceuticals-pyrukynd 2025-01-12T11:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/btk-degraders-offer-new-hope-for-patients-with-pretreated-b-cell-malignancies 2025-01-12T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/btk-degraders-offer-new-hope-for-patients-with-pretreated-b-cell-malignancies 2025-01-12T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2025-cancer-screening-guidelines-update-key-changes-in-breast-cervical-and-colorectal-cancer-detection 2025-01-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2025-cancer-screening-guidelines-update-key-changes-in-breast-cervical-and-colorectal-cancer-detection 2025-01-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-evaluates-diagnostic-accuracy-of-sentinel-lymph-node-biopsy-and-wire-localized-clipped-node-in-breast-cancer-patients 2025-01-12T07:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-evaluates-diagnostic-accuracy-of-sentinel-lymph-node-biopsy-and-wire-localized-clipped-node-in-breast-cancer-patients 2025-01-12T07:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-transforms-gi-cancer-treatment-landscape-moffitt-expert-highlights-role-of-targeted-therapies 2025-01-12T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-transforms-gi-cancer-treatment-landscape-moffitt-expert-highlights-role-of-targeted-therapies 2025-01-12T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/community-engagement-key-to-building-trust-and-improving-healthcare-equity-in-minority-populations 2025-01-12T06:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-engagement-key-to-building-trust-and-improving-healthcare-equity-in-minority-populations 2025-01-12T06:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/early-onset-active-ibd-strongly-correlates-with-increased-psychiatric-disorders-and-medication-use 2025-01-12T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-onset-active-ibd-strongly-correlates-with-increased-psychiatric-disorders-and-medication-use 2025-01-12T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-critical-need-for-standardized-aav-measurements-in-gene-therapy-development 2025-01-12T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-critical-need-for-standardized-aav-measurements-in-gene-therapy-development 2025-01-12T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-initiates-phase-1b-clinical-trial-precise-ad-in-alzheimer-s-disease 2025-01-12T03:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promis-neurosciences-initiates-phase-1b-clinical-trial-precise-ad-in-alzheimer-s-disease 2025-01-12T03:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/regor-releases-phase-2a-topline-results-for-rgt-075-an-oral-once-daily-small-molecule-glp-1r-agonist 2025-01-12T03:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regor-releases-phase-2a-topline-results-for-rgt-075-an-oral-once-daily-small-molecule-glp-1r-agonist 2025-01-12T03:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/top-5-dermatology-news-highlights-january-5-10 2025-01-12T02:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-5-dermatology-news-highlights-january-5-10 2025-01-12T02:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/wells-fargo-lowers-intellia-therapeutics-price-target-to-60 2025-01-12T00:41:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wells-fargo-lowers-intellia-therapeutics-price-target-to-60 2025-01-12T00:41:15+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-and-mmv-advance-new-malaria-drug-combination-to-phase-3 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-and-mmv-advance-new-malaria-drug-combination-to-phase-3 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-oms721-for-iga-nephropathy 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-oms721-for-iga-nephropathy 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/csl-and-travere-near-eu-approval-for-igan-drug-sparsentan 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/csl-and-travere-near-eu-approval-for-igan-drug-sparsentan 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-opzelura-as-first-topical-jak-inhibitor-for-atopic-dermatitis 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-opzelura-as-first-topical-jak-inhibitor-for-atopic-dermatitis 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-patients-gain-early-access-to-duchenne-muscular-dystrophy-drug-through-eams 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-patients-gain-early-access-to-duchenne-muscular-dystrophy-drug-through-eams 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-s-opdivo-yervoy-combo-shows-survival-benefit-in-first-line-liver-cancer-treatment 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-s-opdivo-yervoy-combo-shows-survival-benefit-in-first-line-liver-cancer-treatment 2025-01-11T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-protocol-for-young-empowered-strong-yes-a-randomized-controlled-trial-for-young-breast-cancer-survivors 2025-01-11T22:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-protocol-for-young-empowered-strong-yes-a-randomized-controlled-trial-for-young-breast-cancer-survivors 2025-01-11T22:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/vesper-initiates-phase-1b-2a-sort-in-2-trial-of-ves001-in-genetically-mutated-frontotemporal-dementia 2025-01-11T22:09:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesper-initiates-phase-1b-2a-sort-in-2-trial-of-ves001-in-genetically-mutated-frontotemporal-dementia 2025-01-11T22:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-treatment-sequencing-for-her2-mutated-nsclc 2025-01-11T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-treatment-sequencing-for-her2-mutated-nsclc 2025-01-11T21:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-receives-buy-rating-due-to-escharex-s-market-potential 2025-01-11T20:31:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediwound-receives-buy-rating-due-to-escharex-s-market-potential 2025-01-11T20:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/optimistic-outlook-for-gh-research-promising-phase-2a-results-and-favorable-safety-profile 2025-01-11T19:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optimistic-outlook-for-gh-research-promising-phase-2a-results-and-favorable-safety-profile 2025-01-11T19:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/kidney-cancer-research-consortium-efforts-may-improve-treatment-outcomes 2025-01-11T18:08:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kidney-cancer-research-consortium-efforts-may-improve-treatment-outcomes 2025-01-11T18:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-pembrolizumab-maintains-survival-benefit-in-renal-cell-carcinoma 2025-01-11T18:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-pembrolizumab-maintains-survival-benefit-in-renal-cell-carcinoma 2025-01-11T18:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-use-linked-to-reduced-pancreatic-cancer-risk-in-type-2-diabetes-patients 2025-01-11T17:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspirin-use-linked-to-reduced-pancreatic-cancer-risk-in-type-2-diabetes-patients 2025-01-11T17:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-transforms-life-of-nisga-a-and-haisla-toddler 2025-01-11T15:54:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-transforms-life-of-nisga-a-and-haisla-toddler 2025-01-11T15:54:55+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-holding-company-advances-in-clinical-trials-and-strategic-pipeline-developments 2025-01-11T15:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arvinas-holding-company-advances-in-clinical-trials-and-strategic-pipeline-developments 2025-01-11T15:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-recruiting-participants-for-norovirus-mrna-vaccine-clinical-trial 2025-01-11T15:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-recruiting-participants-for-norovirus-mrna-vaccine-clinical-trial 2025-01-11T15:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/global-analysis-reveals-26-mental-health-resource-websites-for-dermatology-patients 2025-01-11T15:00:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-analysis-reveals-26-mental-health-resource-websites-for-dermatology-patients 2025-01-11T15:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/immunis-secures-25-million-in-series-a-1-financing-for-clinical-trials 2025-01-11T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunis-secures-25-million-in-series-a-1-financing-for-clinical-trials 2025-01-11T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/red-light-exposure-may-help-reduce-risk-of-blood-clots 2025-01-11T13:59:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/red-light-exposure-may-help-reduce-risk-of-blood-clots 2025-01-11T13:59:20+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-announces-exclusive-license-agreement-for-skb378-hbm9378-an-anti-tslp-monoclonal-antibody 2025-01-11T11:46:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-announces-exclusive-license-agreement-for-skb378-hbm9378-an-anti-tslp-monoclonal-antibody 2025-01-11T11:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/fore-biotherapeutics-highlights-pipeline-achievements-for-its-oncology-programme 2025-01-11T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fore-biotherapeutics-highlights-pipeline-achievements-for-its-oncology-programme 2025-01-11T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/topline-results-from-phase-2b-clinical-trial-of-ubx1325-for-dme-expected-in-q1-2025 2025-01-11T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/topline-results-from-phase-2b-clinical-trial-of-ubx1325-for-dme-expected-in-q1-2025 2025-01-11T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-in-norovirus-vaccine-development-with-phase-3-clinical-trial 2025-01-11T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-advances-in-norovirus-vaccine-development-with-phase-3-clinical-trial 2025-01-11T10:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-dyn-101-demonstrates-promising-clinical-results-in-dm1-program 2025-01-11T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-dyn-101-demonstrates-promising-clinical-results-in-dm1-program 2025-01-11T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/wildfire-smoke-exposure-poses-immediate-and-long-term-respiratory-risks-warns-pulmonologist 2025-01-11T08:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wildfire-smoke-exposure-poses-immediate-and-long-term-respiratory-risks-warns-pulmonologist 2025-01-11T08:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-incorporated-faces-setbacks-in-clinical-trials 2025-01-11T08:08:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-incorporated-faces-setbacks-in-clinical-trials 2025-01-11T08:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/ziziphus-jujube-syrup-shows-promise-in-treating-pediatric-functional-constipation 2025-01-11T07:40:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ziziphus-jujube-syrup-shows-promise-in-treating-pediatric-functional-constipation 2025-01-11T07:40:33+00:00 hourly 0.9 https://trial.medpath.com/news/affimed-advances-in-innate-cell-engager-therapies-for-cancer-treatment 2025-01-11T07:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affimed-advances-in-innate-cell-engager-therapies-for-cancer-treatment 2025-01-11T07:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-care-evolution-early-detection-and-precision-medicine-reshape-treatment-landscape 2025-01-11T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-care-evolution-early-detection-and-precision-medicine-reshape-treatment-landscape 2025-01-11T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/skin-cancer-disparities-reveal-higher-mortality-rates-among-us-latine-population-despite-lower-incidence 2025-01-11T05:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skin-cancer-disparities-reveal-higher-mortality-rates-among-us-latine-population-despite-lower-incidence 2025-01-11T05:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/student-run-dermatology-clinics-bridge-healthcare-gap-for-underserved-communities 2025-01-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/student-run-dermatology-clinics-bridge-healthcare-gap-for-underserved-communities 2025-01-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-tablet-shows-promise-for-the-control-and-elimination-of-intestinal-worms 2025-01-11T03:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-tablet-shows-promise-for-the-control-and-elimination-of-intestinal-worms 2025-01-11T03:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/neuralink-successfully-implants-brain-device-in-third-patient 2025-01-11T03:18:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuralink-successfully-implants-brain-device-in-third-patient 2025-01-11T03:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/first-line-lenvima-plus-keytruda-misses-mark-in-endometrial-cancer 2025-01-11T02:14:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-line-lenvima-plus-keytruda-misses-mark-in-endometrial-cancer 2025-01-11T02:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/steam-blast-treatment-for-prostate-cancer-investigated-in-clinical-trial 2025-01-11T02:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steam-blast-treatment-for-prostate-cancer-investigated-in-clinical-trial 2025-01-11T02:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/bcrf-supported-research-sheds-light-on-why-patients-stop-responding-to-cdk4-6-inhibitors 2025-01-11T01:40:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcrf-supported-research-sheds-light-on-why-patients-stop-responding-to-cdk4-6-inhibitors 2025-01-11T01:40:39+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-provides-business-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-11T01:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-provides-business-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-11T01:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/could-a-mango-flavoured-pill-end-intestinal-worms 2025-01-11T00:58:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-a-mango-flavoured-pill-end-intestinal-worms 2025-01-11T00:58:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-panel-supports-injection-for-leg-pain-from-herniated-discs 2025-01-11T00:40:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-panel-supports-injection-for-leg-pain-from-herniated-discs 2025-01-11T00:40:06+00:00 hourly 0.9 https://trial.medpath.com/news/rheumagen-secures-15m-in-series-a-funding-to-advance-ra-therapies 2025-01-11T00:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rheumagen-secures-15m-in-series-a-funding-to-advance-ra-therapies 2025-01-11T00:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-s-90000-lymphoma-combination-treatment 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-roche-s-90000-lymphoma-combination-treatment 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-initiates-accelerated-review-for-bluebird-s-gene-therapy-targeting-rare-disease-cald 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-initiates-accelerated-review-for-bluebird-s-gene-therapy-targeting-rare-disease-cald 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-show-promise-in-managing-chronic-kidney-disease-in-real-world-settings 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-show-promise-in-managing-chronic-kidney-disease-in-real-world-settings 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/teva-s-long-acting-schizophrenia-drug-rejected-by-fda 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-s-long-acting-schizophrenia-drug-rejected-by-fda 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-alzheimers-treatment-using-noninvasive-focused-ultrasound 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-alzheimers-treatment-using-noninvasive-focused-ultrasound 2025-01-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-offers-new-hope-for-child-with-rare-genetic-disorder 2025-01-10T23:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-offers-new-hope-for-child-with-rare-genetic-disorder 2025-01-10T23:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-holding-announces-phase-2a-results-for-rgt-075-and-initiates-phase-2b-study-in-the-us 2025-01-10T22:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-holding-announces-phase-2a-results-for-rgt-075-and-initiates-phase-2b-study-in-the-us 2025-01-10T22:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-talicia-gains-major-medicare-coverage-through-humana-part-d-plan 2025-01-10T22:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-s-talicia-gains-major-medicare-coverage-through-humana-part-d-plan 2025-01-10T22:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/research-explores-molecular-dynamics-of-car-t-cells-in-cancer-treatment 2025-01-10T21:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-explores-molecular-dynamics-of-car-t-cells-in-cancer-treatment 2025-01-10T21:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/totus-medicines-announces-successful-phase-1-study-and-expansion-trial-for-tos-358 2025-01-10T21:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/totus-medicines-announces-successful-phase-1-study-and-expansion-trial-for-tos-358 2025-01-10T21:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/yaqrit-appoints-new-ceo-troels-jordansen-to-lead-late-clinical-development-and-commercial-strategy 2025-01-10T20:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yaqrit-appoints-new-ceo-troels-jordansen-to-lead-late-clinical-development-and-commercial-strategy 2025-01-10T20:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-writes-off-3-5b-on-cerevel-drug-after-phase-2-failures 2025-01-10T20:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-writes-off-3-5b-on-cerevel-drug-after-phase-2-failures 2025-01-10T20:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-nk-cell-engagers-show-promise-in-lymphoma-treatment 2025-01-10T20:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-nk-cell-engagers-show-promise-in-lymphoma-treatment 2025-01-10T20:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/nextcure-announces-first-patient-dosed-in-phase-1-study-of-lncb74-for-multiple-cancers 2025-01-10T19:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcure-announces-first-patient-dosed-in-phase-1-study-of-lncb74-for-multiple-cancers 2025-01-10T19:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/monoclonal-antibody-shows-promise-against-dominant-covid-19-variant 2025-01-10T18:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monoclonal-antibody-shows-promise-against-dominant-covid-19-variant 2025-01-10T18:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/surprising-findings-about-blood-cell-mutations-bode-well-for-transplant-recipients 2025-01-10T17:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surprising-findings-about-blood-cell-mutations-bode-well-for-transplant-recipients 2025-01-10T17:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-taiwan-university-hospital-and-abbvie-biopharma-enhance-digital-strategies-for-clinical-trials 2025-01-10T17:45:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-taiwan-university-hospital-and-abbvie-biopharma-enhance-digital-strategies-for-clinical-trials 2025-01-10T17:45:18+00:00 hourly 0.9 https://trial.medpath.com/news/early-control-of-rheumatoid-arthritis-improves-hemostatic-imbalance 2025-01-10T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-control-of-rheumatoid-arthritis-improves-hemostatic-imbalance 2025-01-10T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-pd-1-drug-sasanlimab-shows-promise-in-bladder-cancer-treatment 2025-01-10T16:53:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-pd-1-drug-sasanlimab-shows-promise-in-bladder-cancer-treatment 2025-01-10T16:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-follow-up-of-nrg258-trial-shows-no-survival-difference-between-adjuvant-chemoradiation-and-chemotherapy-in-locally-advanced-endometrial-carcinoma 2025-01-10T16:53:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-follow-up-of-nrg258-trial-shows-no-survival-difference-between-adjuvant-chemoradiation-and-chemotherapy-in-locally-advanced-endometrial-carcinoma 2025-01-10T16:53:12+00:00 hourly 0.9 https://trial.medpath.com/news/mersana-therapeutics-stock-drops-following-phase-1-trial-data-release 2025-01-10T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mersana-therapeutics-stock-drops-following-phase-1-trial-data-release 2025-01-10T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/mediar-therapeutics-partners-with-lilly-to-advance-ipf-treatment 2025-01-10T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediar-therapeutics-partners-with-lilly-to-advance-ipf-treatment 2025-01-10T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/diakonos-oncology-to-present-at-biotech-showcase-2025 2025-01-10T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diakonos-oncology-to-present-at-biotech-showcase-2025 2025-01-10T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/aileron-therapeutics-rebrands-to-rein-therapeutics-focusing-on-orphan-pulmonary-and-fibrosis-treatments 2025-01-10T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aileron-therapeutics-rebrands-to-rein-therapeutics-focusing-on-orphan-pulmonary-and-fibrosis-treatments 2025-01-10T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/barinthus-bio-announces-promising-results-from-phase-2b-hepatitis-b-trial 2025-01-10T16:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barinthus-bio-announces-promising-results-from-phase-2b-hepatitis-b-trial 2025-01-10T16:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-launches-phase-i-avian-influenza-trials-in-us 2025-01-10T16:18:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-launches-phase-i-avian-influenza-trials-in-us 2025-01-10T16:18:21+00:00 hourly 0.9 https://trial.medpath.com/news/dxb-secures-107m-licensing-deal-in-japan-awaits-phase-3-results 2025-01-10T15:44:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dxb-secures-107m-licensing-deal-in-japan-awaits-phase-3-results 2025-01-10T15:44:30+00:00 hourly 0.9 https://trial.medpath.com/news/mersana-therapeutics-receives-buy-rating-based-on-promising-clinical-data-and-strong-financials 2025-01-10T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mersana-therapeutics-receives-buy-rating-based-on-promising-clinical-data-and-strong-financials 2025-01-10T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/rhygaze-secures-usd-86-million-series-a-funding-for-vision-restoration-gene-therapy 2025-01-10T15:16:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhygaze-secures-usd-86-million-series-a-funding-for-vision-restoration-gene-therapy 2025-01-10T15:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-stock-hits-52-week-low-amid-market-challenges 2025-01-10T15:14:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-stock-hits-52-week-low-amid-market-challenges 2025-01-10T15:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/vistagen-launches-repeat-dose-study-of-fasedienol-for-social-anxiety-disorder-treatment 2025-01-10T15:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vistagen-launches-repeat-dose-study-of-fasedienol-for-social-anxiety-disorder-treatment 2025-01-10T15:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/4d-molecular-therapeutics-shifts-focus-to-late-stage-gene-therapy-for-eye-disease 2025-01-10T14:46:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4d-molecular-therapeutics-shifts-focus-to-late-stage-gene-therapy-for-eye-disease 2025-01-10T14:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/spero-therapeutics-advances-phase-iii-pivot-po-trial-for-tebipenem-hbr 2025-01-10T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spero-therapeutics-advances-phase-iii-pivot-po-trial-for-tebipenem-hbr 2025-01-10T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/marea-therapeutics-announces-positive-phase-ii-data-for-cholesterol-lowering-antibody 2025-01-10T14:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marea-therapeutics-announces-positive-phase-ii-data-for-cholesterol-lowering-antibody 2025-01-10T14:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-outlines-2025-strategic-priorities-and-recent-hematology-portfolio-achievements 2025-01-10T14:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-outlines-2025-strategic-priorities-and-recent-hematology-portfolio-achievements 2025-01-10T14:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-announces-continued-neutralizing-activity-of-pemgarda-against-dominant-sars-cov-2-variant-xec 2025-01-10T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-announces-continued-neutralizing-activity-of-pemgarda-against-dominant-sars-cov-2-variant-xec 2025-01-10T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/chardan-initiates-unity-biotechnology-stock-with-buy-rating-cites-senolytic-ubx1325-potential 2025-01-10T14:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chardan-initiates-unity-biotechnology-stock-with-buy-rating-cites-senolytic-ubx1325-potential 2025-01-10T14:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-subcutaneous-pd-1-blocker-achieves-significant-efficacy-in-phase-iii-bladder-cancer-trial 2025-01-10T14:03:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-subcutaneous-pd-1-blocker-achieves-significant-efficacy-in-phase-iii-bladder-cancer-trial 2025-01-10T14:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-clear-trial-evaluating-organ-specific-progression-patterns 2025-01-10T14:00:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-clear-trial-evaluating-organ-specific-progression-patterns 2025-01-10T14:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-announces-first-patient-infused-in-phase-1-celestial-301-clinical-trial-of-synkir-310 2025-01-10T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-announces-first-patient-infused-in-phase-1-celestial-301-clinical-trial-of-synkir-310 2025-01-10T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-announces-ce-mark-approval-for-dual-energy-thermocool-smarttouchtm-sf-catheter 2025-01-10T13:59:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-announces-ce-mark-approval-for-dual-energy-thermocool-smarttouchtm-sf-catheter 2025-01-10T13:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/alyea-therapeutics-to-present-at-biotech-showcase-2025 2025-01-10T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alyea-therapeutics-to-present-at-biotech-showcase-2025 2025-01-10T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/restem-announces-key-business-objectives-for-2025-and-corporate-update 2025-01-10T13:28:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restem-announces-key-business-objectives-for-2025-and-corporate-update 2025-01-10T13:28:27+00:00 hourly 0.9 https://trial.medpath.com/news/newamsterdam-pharma-highlights-2024-achievements-and-outlines-2025-strategic-priorities 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newamsterdam-pharma-highlights-2024-achievements-and-outlines-2025-strategic-priorities 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/4dmt-announces-positive-interim-data-from-4d-150-spectra-clinical-trial-in-dme-and-alignment-with-fda-on-registrational-path 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4dmt-announces-positive-interim-data-from-4d-150-spectra-clinical-trial-in-dme-and-alignment-with-fda-on-registrational-path 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/barinthus-bio-shifts-focus-to-immunology-and-inflammation-announces-financial-restructuring 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/barinthus-bio-shifts-focus-to-immunology-and-inflammation-announces-financial-restructuring 2025-01-10T13:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-and-pharma-developments-j-j-pfizer-gsk-and-novo-nordisk 2025-01-10T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-updates-and-pharma-developments-j-j-pfizer-gsk-and-novo-nordisk 2025-01-10T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-announces-phase-1-intercept-ad-study-publication 2025-01-10T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acumen-announces-phase-1-intercept-ad-study-publication 2025-01-10T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/intensity-therapeutics-advances-in-breast-cancer-treatment-with-int230-6 2025-01-10T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intensity-therapeutics-advances-in-breast-cancer-treatment-with-int230-6 2025-01-10T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rhythm-pharmaceuticals-reports-preliminary-2024-financials-and-clinical-trial-progress 2025-01-10T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-reports-preliminary-2024-financials-and-clinical-trial-progress 2025-01-10T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-ventris-medical-s-backpack-for-orthopaedic-use 2025-01-10T12:50:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-ventris-medical-s-backpack-for-orthopaedic-use 2025-01-10T12:50:57+00:00 hourly 0.9 https://trial.medpath.com/news/study-links-higher-psoriasis-acceptance-to-improved-clinical-outcomes-and-quality-of-life 2025-01-10T12:47:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-links-higher-psoriasis-acceptance-to-improved-clinical-outcomes-and-quality-of-life 2025-01-10T12:47:12+00:00 hourly 0.9 https://trial.medpath.com/news/crinetics-announces-positive-topline-results-from-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia-cah 2025-01-10T12:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crinetics-announces-positive-topline-results-from-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia-cah 2025-01-10T12:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/passage-bio-announces-data-from-uplift-d-study-in-ftd-grn 2025-01-10T12:31:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/passage-bio-announces-data-from-uplift-d-study-in-ftd-grn 2025-01-10T12:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-confirms-ibrutinib-s-safety-and-efficacy-in-japanese-cll-sll-patients 2025-01-10T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-confirms-ibrutinib-s-safety-and-efficacy-in-japanese-cll-sll-patients 2025-01-10T12:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-announces-strategic-business-update-and-2025-priorities 2025-01-10T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-mabs-announces-strategic-business-update-and-2025-priorities 2025-01-10T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/vertigo-global-clinical-trials-review-2024-now-available 2025-01-10T12:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertigo-global-clinical-trials-review-2024-now-available 2025-01-10T12:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/alentis-therapeutics-reports-positive-results-from-organ-fibrosis-treatment-trials 2025-01-10T12:18:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alentis-therapeutics-reports-positive-results-from-organ-fibrosis-treatment-trials 2025-01-10T12:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/nektar-therapeutics-completes-enrollment-in-phase-2b-study-for-atopic-dermatitis-treatment 2025-01-10T12:14:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nektar-therapeutics-completes-enrollment-in-phase-2b-study-for-atopic-dermatitis-treatment 2025-01-10T12:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-therapeutics-announces-2025-milestones-and-corporate-update 2025-01-10T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-therapeutics-announces-2025-milestones-and-corporate-update 2025-01-10T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/neumirna-raises-eur20m-for-clinical-trials-of-epilepsy-drug 2025-01-10T12:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumirna-raises-eur20m-for-clinical-trials-of-epilepsy-drug 2025-01-10T12:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/gh-research-announces-primary-endpoint-met-in-two-phase-2a-trials 2025-01-10T12:02:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gh-research-announces-primary-endpoint-met-in-two-phase-2a-trials 2025-01-10T12:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/arvinas-plans-two-phase-3-trials-for-breakthrough-breast-cancer-treatment 2025-01-10T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arvinas-plans-two-phase-3-trials-for-breakthrough-breast-cancer-treatment 2025-01-10T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-in-focus-for-insider-activity-catalysts-ahead 2025-01-10T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-in-focus-for-insider-activity-catalysts-ahead 2025-01-10T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-reports-promising-clinical-data-for-dm1-and-dmd-treatments 2025-01-10T11:41:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-reports-promising-clinical-data-for-dm1-and-dmd-treatments 2025-01-10T11:41:28+00:00 hourly 0.9 https://trial.medpath.com/news/ouro-medicines-launches-with-120m-to-develop-t-cell-engagers-for-autoimmune-diseases 2025-01-10T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ouro-medicines-launches-with-120m-to-develop-t-cell-engagers-for-autoimmune-diseases 2025-01-10T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-mersana-s-breast-cancer-drug-emi-le-for-expanded-use 2025-01-10T11:13:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-mersana-s-breast-cancer-drug-emi-le-for-expanded-use 2025-01-10T11:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/orexo-announces-positive-data-from-clinical-study-of-ox640-evaluating-allergic-reactions 2025-01-10T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orexo-announces-positive-data-from-clinical-study-of-ox640-evaluating-allergic-reactions 2025-01-10T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-status-to-mersana-s-breast-cancer-drug-for-expanded-use 2025-01-10T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-status-to-mersana-s-breast-cancer-drug-for-expanded-use 2025-01-10T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/mersana-therapeutics-announces-positive-initial-clinical-data-from-phase-1-trial-of-emiltatug-ledadotin 2025-01-10T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mersana-therapeutics-announces-positive-initial-clinical-data-from-phase-1-trial-of-emiltatug-ledadotin 2025-01-10T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-new-ldt-regulations-face-industry-pushback-and-legislative-uncertainty 2025-01-10T09:43:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-new-ldt-regulations-face-industry-pushback-and-legislative-uncertainty 2025-01-10T09:43:44+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-completes-phase-2-enrollment-ahead-of-schedule-for-io102-io103-cancer-vaccine-trial 2025-01-10T08:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-completes-phase-2-enrollment-ahead-of-schedule-for-io102-io103-cancer-vaccine-trial 2025-01-10T08:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/comparative-study-of-whole-genome-transcriptome-sequencing-vs-panel-sequencing-in-cancer-treatment 2025-01-10T08:29:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comparative-study-of-whole-genome-transcriptome-sequencing-vs-panel-sequencing-in-cancer-treatment 2025-01-10T08:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/lava-therapeutics-initiates-phase-1-trial-for-novel-cancer-treatment-lava-1266 2025-01-10T08:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lava-therapeutics-initiates-phase-1-trial-for-novel-cancer-treatment-lava-1266 2025-01-10T08:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-review-of-gsk-plc-s-prefilled-shingrix-syringe-for-vaccine-approval 2025-01-10T08:12:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-review-of-gsk-plc-s-prefilled-shingrix-syringe-for-vaccine-approval 2025-01-10T08:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-samsung-bioepis-launch-epysqli-a-30-discounted-biosimilar-to-soliris-for-rare-diseases 2025-01-10T08:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-and-samsung-bioepis-launch-epysqli-a-30-discounted-biosimilar-to-soliris-for-rare-diseases 2025-01-10T08:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-biosciences-receives-fda-ind-clearance-for-phase-2-study-of-tyra-300-in-non-muscle-invasive-bladder-cancer 2025-01-10T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-biosciences-receives-fda-ind-clearance-for-phase-2-study-of-tyra-300-in-non-muscle-invasive-bladder-cancer 2025-01-10T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cargo-therapeutics-announces-2025-milestones-and-corporate-update 2025-01-10T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cargo-therapeutics-announces-2025-milestones-and-corporate-update 2025-01-10T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/health-literacy-crisis-88-of-adults-struggle-with-medical-information-understanding 2025-01-10T07:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-literacy-crisis-88-of-adults-struggle-with-medical-information-understanding 2025-01-10T07:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/sn-bioscience-advances-snb-101-to-phase-2-clinical-trials-with-fda-ind-clearance 2025-01-10T07:45:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sn-bioscience-advances-snb-101-to-phase-2-clinical-trials-with-fda-ind-clearance 2025-01-10T07:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-investigational-mri-contrast-agent-gadoquatrane-meets-primary-and-main-secondary-endpoints-in-phase-iii-studies 2025-01-10T07:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-investigational-mri-contrast-agent-gadoquatrane-meets-primary-and-main-secondary-endpoints-in-phase-iii-studies 2025-01-10T07:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/global-clinical-trials-for-herpes-zoster-shingles-in-2024-a-comprehensive-review 2025-01-10T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-clinical-trials-for-herpes-zoster-shingles-in-2024-a-comprehensive-review 2025-01-10T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/atai-life-sciences-strengthens-leadership-team-to-advance-psychedelic-therapeutics-for-mental-health 2025-01-10T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atai-life-sciences-strengthens-leadership-team-to-advance-psychedelic-therapeutics-for-mental-health 2025-01-10T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-new-and-supplemental-approvals-in-december 2025-01-10T06:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-new-and-supplemental-approvals-in-december 2025-01-10T06:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/ai-breakthrough-in-cancer-detection-and-treatment-major-advances-in-breast-cancer-screening-and-immunotherapy-prediction 2025-01-10T06:22:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-breakthrough-in-cancer-detection-and-treatment-major-advances-in-breast-cancer-screening-and-immunotherapy-prediction 2025-01-10T06:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/izotropic-files-pre-submission-with-u-s-fda-for-breast-cancer-screening 2025-01-10T06:20:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/izotropic-files-pre-submission-with-u-s-fda-for-breast-cancer-screening 2025-01-10T06:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/novel-respiratory-and-emg-patterns-identified-as-reliable-indicators-of-dysphagia-in-myasthenia-gravis 2025-01-10T06:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-respiratory-and-emg-patterns-identified-as-reliable-indicators-of-dysphagia-in-myasthenia-gravis 2025-01-10T06:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biosciences-arcus-platform-shows-promising-clinical-outcomes-in-gene-editing-trial 2025-01-10T05:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biosciences-arcus-platform-shows-promising-clinical-outcomes-in-gene-editing-trial 2025-01-10T05:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/neumora-s-depression-drug-navacaprant-fails-phase-iii-trial-shares-plummet 2025-01-10T04:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neumora-s-depression-drug-navacaprant-fails-phase-iii-trial-shares-plummet 2025-01-10T04:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/spinal-cord-injury-treatment-market-to-see-significant-growth-by-2034 2025-01-10T02:45:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spinal-cord-injury-treatment-market-to-see-significant-growth-by-2034 2025-01-10T02:45:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-drug-review-chief-patrizia-cavazzoni-announces-departure-amid-leadership-transitions 2025-01-10T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-drug-review-chief-patrizia-cavazzoni-announces-departure-amid-leadership-transitions 2025-01-10T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/early-stage-alzheimer-s-new-guidelines-reveal-10-year-window-for-intervention-before-symptoms 2025-01-10T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-stage-alzheimer-s-new-guidelines-reveal-10-year-window-for-intervention-before-symptoms 2025-01-10T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-drug-hope-for-prostate-cancer-patients 2025-01-10T00:00:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-drug-hope-for-prostate-cancer-patients 2025-01-10T00:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accelerates-review-for-bayer-s-parkinson-s-stem-cell-therapy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accelerates-review-for-bayer-s-parkinson-s-stem-cell-therapy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-discovery-unveils-cancer-therapy-breakthrough 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-discovery-unveils-cancer-therapy-breakthrough 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-diabetic-retinopathy-clinical-trials-landscape-analysis-reveals-key-research-trends-for-2024 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-diabetic-retinopathy-clinical-trials-landscape-analysis-reveals-key-research-trends-for-2024 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-questions-efficacy-of-spinal-fusion-over-decompression-alone-for-degenerative-spondylolisthesis 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-questions-efficacy-of-spinal-fusion-over-decompression-alone-for-degenerative-spondylolisthesis 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/obesity-biotech-metsera-files-for-a-100-million-ipo 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obesity-biotech-metsera-files-for-a-100-million-ipo 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/efficacy-and-safety-of-liwei-capsule-in-chronic-non-atrophic-gastritis-with-erosions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efficacy-and-safety-of-liwei-capsule-in-chronic-non-atrophic-gastritis-with-erosions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cepheus-study-validates-mrd-as-critical-biomarker-in-multiple-myeloma-treatment 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cepheus-study-validates-mrd-as-critical-biomarker-in-multiple-myeloma-treatment 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-initiates-review-of-rocket-pharma-s-gene-therapy-for-fanconi-anaemia 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-initiates-review-of-rocket-pharma-s-gene-therapy-for-fanconi-anaemia 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-inc-advances-in-neuroinflammatory-disease-treatments 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-inc-advances-in-neuroinflammatory-disease-treatments 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-s-preprint-highlights-galectin-3-modulation-as-key-to-enhancing-immunotherapy-efficacy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxytran-s-preprint-highlights-galectin-3-modulation-as-key-to-enhancing-immunotherapy-efficacy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/latest-updates-on-fda-approvals-and-processes 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latest-updates-on-fda-approvals-and-processes 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/belatacept-use-and-risk-of-post-transplant-lymphoproliferative-disorder-in-kidney-transplant-recipients 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belatacept-use-and-risk-of-post-transplant-lymphoproliferative-disorder-in-kidney-transplant-recipients 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4dmt-prioritizes-4d-150-for-wet-amd-and-dme-and-4d-710-for-cystic-fibrosis-in-strategic-pipeline-focus 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4dmt-prioritizes-4d-150-for-wet-amd-and-dme-and-4d-710-for-cystic-fibrosis-in-strategic-pipeline-focus 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-largest-proteomics-trial-launched-by-uk-biobank 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-largest-proteomics-trial-launched-by-uk-biobank 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/compass-pathways-announces-pricing-of-underwritten-offering 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-pathways-announces-pricing-of-underwritten-offering 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/inz-701-shows-promising-survival-benefits-in-infants-with-enpp1-deficiency-trial-enrollment-complete 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inz-701-shows-promising-survival-benefits-in-infants-with-enpp1-deficiency-trial-enrollment-complete 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-announces-3-5b-impairment-charge-due-to-failed-schizophrenia-drug 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-announces-3-5b-impairment-charge-due-to-failed-schizophrenia-drug 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/self-destruct-tb-vaccine-shows-promise-in-boosting-safety-efficacy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/self-destruct-tb-vaccine-shows-promise-in-boosting-safety-efficacy 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-dengue-vaccine-tak-003-approved-for-use-in-argentina 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-dengue-vaccine-tak-003-approved-for-use-in-argentina 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-updates-trials-stocks-and-acquisitions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-updates-trials-stocks-and-acquisitions 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-shows-improvement-in-family-centered-care-practices-in-nicus-following-educational-intervention 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-shows-improvement-in-family-centered-care-practices-in-nicus-following-educational-intervention 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/insights-into-clinical-trials-and-research-practices 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insights-into-clinical-trials-and-research-practices 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lokon-pharma-advances-in-cancer-treatment-with-load-family-clinical-trials 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lokon-pharma-advances-in-cancer-treatment-with-load-family-clinical-trials 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug-tukysa 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug-tukysa 2025-01-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cascada-silver-launches-phase-ii-drilling-at-angie-project 2025-01-09T22:52:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cascada-silver-launches-phase-ii-drilling-at-angie-project 2025-01-09T22:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/chordia-therapeutics-secures-orphan-drug-designation-for-rogocekib-in-the-u-s 2025-01-09T22:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chordia-therapeutics-secures-orphan-drug-designation-for-rogocekib-in-the-u-s 2025-01-09T22:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-with-multiple-myeloma-dosed-in-esobiotec-s-trial-for-in-vivo-car-t-eso-t01 2025-01-09T22:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-with-multiple-myeloma-dosed-in-esobiotec-s-trial-for-in-vivo-car-t-eso-t01 2025-01-09T22:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-bbo-8520-fast-track-designation-for-krasg12c-mutant-mnsclc 2025-01-09T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-bbo-8520-fast-track-designation-for-krasg12c-mutant-mnsclc 2025-01-09T21:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/igm-biosciences-halts-development-of-top-drugs-and-announces-workforce-reduction 2025-01-09T21:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igm-biosciences-halts-development-of-top-drugs-and-announces-workforce-reduction 2025-01-09T21:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/aptose-announces-first-aml-patients-dosed-with-tuspetinib-triplet-frontline-therapy-in-tuscany-trial 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptose-announces-first-aml-patients-dosed-with-tuspetinib-triplet-frontline-therapy-in-tuscany-trial 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/igm-biosciences-downgraded-by-bmo-capital-following-strategic-update 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igm-biosciences-downgraded-by-bmo-capital-following-strategic-update 2025-01-09T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intellia-therapeutics-announces-strategic-reorganization-and-2025-milestones 2025-01-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-sa-advances-in-phase-3-trials-for-ulcerative-colitis-treatment 2025-01-09T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-sa-advances-in-phase-3-trials-for-ulcerative-colitis-treatment 2025-01-09T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/cage-bio-announces-phase-2b-trial-for-cgb-500-in-atopic-dermatitis-treatment 2025-01-09T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cage-bio-announces-phase-2b-trial-for-cgb-500-in-atopic-dermatitis-treatment 2025-01-09T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-discontinuations-of-ocrelizumab-in-ms-comparable-to-pivotal-trials 2025-01-09T19:25:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-discontinuations-of-ocrelizumab-in-ms-comparable-to-pivotal-trials 2025-01-09T19:25:25+00:00 hourly 0.9 https://trial.medpath.com/news/astra-merck-drugs-set-to-shake-up-liver-cancer-treatment 2025-01-09T18:25:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astra-merck-drugs-set-to-shake-up-liver-cancer-treatment 2025-01-09T18:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-concludes-enrolment-in-phase-ii-multiple-sclerosis-therapy-trial 2025-01-09T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-concludes-enrolment-in-phase-ii-multiple-sclerosis-therapy-trial 2025-01-09T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/arovella-secures-20m-for-phase-1-clinical-trial-and-pipeline-expansion 2025-01-09T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arovella-secures-20m-for-phase-1-clinical-trial-and-pipeline-expansion 2025-01-09T16:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-car-t-clinical-trials-underway-at-roswell-park-for-solid-tumor-non-cancerous-diseases 2025-01-09T16:42:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-car-t-clinical-trials-underway-at-roswell-park-for-solid-tumor-non-cancerous-diseases 2025-01-09T16:42:51+00:00 hourly 0.9 https://trial.medpath.com/news/new-phase-2a-findings-on-img-007-treatment-for-atopic-dermatitis-show-promising-results 2025-01-09T16:40:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-phase-2a-findings-on-img-007-treatment-for-atopic-dermatitis-show-promising-results 2025-01-09T16:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ia-study-of-novel-anti-her2-antibody-drug-conjugate-gq1001-shows-promise-in-treating-her2-positive-advanced-solid-tumors 2025-01-09T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ia-study-of-novel-anti-her2-antibody-drug-conjugate-gq1001-shows-promise-in-treating-her2-positive-advanced-solid-tumors 2025-01-09T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-achieves-key-milestone-in-phase-3-abtect-trial-enrollment 2025-01-09T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-achieves-key-milestone-in-phase-3-abtect-trial-enrollment 2025-01-09T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-care-after-donor-stem-cell-transplant-can-be-safely-shared-between-transplant-centers-and-local-oncologists 2025-01-09T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-care-after-donor-stem-cell-transplant-can-be-safely-shared-between-transplant-centers-and-local-oncologists 2025-01-09T16:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-upgraded-to-overweight-by-morgan-stanley 2025-01-09T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-upgraded-to-overweight-by-morgan-stanley 2025-01-09T16:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-approach-to-cancer-treatment-targeted-protein-degradation 2025-01-09T16:28:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-approach-to-cancer-treatment-targeted-protein-degradation 2025-01-09T16:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/thetis-pharmaceuticals-secures-9m-funding-to-advance-novel-oral-ibd-treatment 2025-01-09T16:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thetis-pharmaceuticals-secures-9m-funding-to-advance-novel-oral-ibd-treatment 2025-01-09T16:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/stroke-trial-tests-innovative-device-to-combat-arm-weakness 2025-01-09T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stroke-trial-tests-innovative-device-to-combat-arm-weakness 2025-01-09T16:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/durvalumab-plus-vaccine-therapy-shows-promise-in-bcg-unresponsive-nmibc 2025-01-09T16:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvalumab-plus-vaccine-therapy-shows-promise-in-bcg-unresponsive-nmibc 2025-01-09T16:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/gildeuretinol-shows-promise-in-halting-stargardt-disease-progression 2025-01-09T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gildeuretinol-shows-promise-in-halting-stargardt-disease-progression 2025-01-09T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/non-histone-lactylation-emerges-as-key-regulator-in-cancer-progression-and-therapeutic-target 2025-01-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-histone-lactylation-emerges-as-key-regulator-in-cancer-progression-and-therapeutic-target 2025-01-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/three-pronged-treatment-improves-prognosis-for-inoperable-liver-cancer 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-pronged-treatment-improves-prognosis-for-inoperable-liver-cancer 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/tenpoint-therapeutics-announces-positive-topline-data-from-brio-ii-phase-3-trial 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenpoint-therapeutics-announces-positive-topline-data-from-brio-ii-phase-3-trial 2025-01-09T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/9mw2821-toripalimab-granted-breakthrough-therapy-designation-in-china-for-muc 2025-01-09T15:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/9mw2821-toripalimab-granted-breakthrough-therapy-designation-in-china-for-muc 2025-01-09T15:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/study-on-enhanced-oral-hygiene-program-for-cleft-patients 2025-01-09T15:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-on-enhanced-oral-hygiene-program-for-cleft-patients 2025-01-09T15:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/cristcot-s-phase-iii-ulcerative-colitis-suppository-trial-meets-endpoints 2025-01-09T15:28:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cristcot-s-phase-iii-ulcerative-colitis-suppository-trial-meets-endpoints 2025-01-09T15:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/argon-medical-announces-first-patient-enrollment-in-clean-pe-study-for-pulmonary-embolism-treatment 2025-01-09T15:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argon-medical-announces-first-patient-enrollment-in-clean-pe-study-for-pulmonary-embolism-treatment 2025-01-09T15:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-assessed-acupuncture-for-severe-combat-related-ptsd 2025-01-09T15:16:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-assessed-acupuncture-for-severe-combat-related-ptsd 2025-01-09T15:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biosciences-announces-complete-clinical-response-in-otc-hope-study-with-ecur-506 2025-01-09T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biosciences-announces-complete-clinical-response-in-otc-hope-study-with-ecur-506 2025-01-09T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/effects-of-ultrasound-guided-recruitment-manoeuvres-on-postoperative-pulmonary-complications-in-obese-patients 2025-01-09T14:31:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/effects-of-ultrasound-guided-recruitment-manoeuvres-on-postoperative-pulmonary-complications-in-obese-patients 2025-01-09T14:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials 2025-01-09T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofidelity-and-cellcarta-partner-to-deploy-aspyre-lung-in-global-clinical-trials 2025-01-09T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-cabometyx-cancer-drug-review-advances-as-fda-drops-advisory-meeting-requirement 2025-01-09T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-cabometyx-cancer-drug-review-advances-as-fda-drops-advisory-meeting-requirement 2025-01-09T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/limited-benefits-of-ctdna-testing-in-colorectal-cancer-surveillance-study-finds 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/limited-benefits-of-ctdna-testing-in-colorectal-cancer-surveillance-study-finds 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-supports-efficacy-of-opdivo-plus-yervoy-in-mrcc-treatment 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-supports-efficacy-of-opdivo-plus-yervoy-in-mrcc-treatment 2025-01-09T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abdera-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-09T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abdera-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-09T13:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/first-u-s-h5n1-bird-flu-death-reported-in-louisiana-amid-low-overall-risk 2025-01-09T13:36:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-u-s-h5n1-bird-flu-death-reported-in-louisiana-amid-low-overall-risk 2025-01-09T13:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/mineralys-therapeutics-advances-lorundrostat-to-phase-2-trials 2025-01-09T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mineralys-therapeutics-advances-lorundrostat-to-phase-2-trials 2025-01-09T13:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-announces-r289-granted-orphan-drug-designation-by-the-fda-for-mds 2025-01-09T13:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-announces-r289-granted-orphan-drug-designation-by-the-fda-for-mds 2025-01-09T13:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-combined-with-cisplatin-and-radiotherapy-shows-improved-disease-free-survival-in-locally-advanced-scchn 2025-01-09T13:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-combined-with-cisplatin-and-radiotherapy-shows-improved-disease-free-survival-in-locally-advanced-scchn 2025-01-09T13:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-nipocalimab-receives-fda-priority-review-for-generalized-myasthenia-gravis-treatment 2025-01-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-nipocalimab-receives-fda-priority-review-for-generalized-myasthenia-gravis-treatment 2025-01-09T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-advances-oncology-pipeline-with-ind-submission-for-ndi-219216 2025-01-09T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimbus-therapeutics-advances-oncology-pipeline-with-ind-submission-for-ndi-219216 2025-01-09T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/affinia-therapeutics-announces-development-candidate-for-bag3-dcm-and-completion-of-pre-ind-meeting-with-the-fda 2025-01-09T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affinia-therapeutics-announces-development-candidate-for-bag3-dcm-and-completion-of-pre-ind-meeting-with-the-fda 2025-01-09T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapport-therapeutics-announces-new-phase-1-data-supporting-rap-219-s-potential-for-cns-disorders 2025-01-09T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapport-therapeutics-announces-new-phase-1-data-supporting-rap-219-s-potential-for-cns-disorders 2025-01-09T12:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-s-cancer-drug-lyt-200-secures-fda-fast-track-status-for-leukemia-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-s-cancer-drug-lyt-200-secures-fda-fast-track-status-for-leukemia-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/zentalis-cancer-drug-azenosertib-receives-fda-fast-track-status-for-ovarian-cancer-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentalis-cancer-drug-azenosertib-receives-fda-fast-track-status-for-ovarian-cancer-treatment 2025-01-09T12:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/peerbridge-health-launches-cor-insight-trial-for-ai-enabled-cardiac-and-cardiopulmonary-diagnostics 2025-01-09T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peerbridge-health-launches-cor-insight-trial-for-ai-enabled-cardiac-and-cardiopulmonary-diagnostics 2025-01-09T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate 2025-01-09T11:54:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate 2025-01-09T11:54:49+00:00 hourly 0.9 https://trial.medpath.com/news/european-pharmaceutical-industry-pushes-for-rapid-digital-package-insert-transition 2025-01-09T11:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-pharmaceutical-industry-pushes-for-rapid-digital-package-insert-transition 2025-01-09T11:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-enhances-partnership-with-agc-biologics-for-advanced-cell-therapy-manufacturing 2025-01-09T11:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-enhances-partnership-with-agc-biologics-for-advanced-cell-therapy-manufacturing 2025-01-09T11:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-share-price-rises-on-positive-clinical-trial-results 2025-01-09T11:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-share-price-rises-on-positive-clinical-trial-results 2025-01-09T11:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/aviceda-therapeutics-secures-207-5-million-series-c-financing-for-geographic-atrophy-treatment 2025-01-09T11:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aviceda-therapeutics-secures-207-5-million-series-c-financing-for-geographic-atrophy-treatment 2025-01-09T11:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-test-oracle-predicts-survival-better-than-current-methods 2025-01-09T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-test-oracle-predicts-survival-better-than-current-methods 2025-01-09T10:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/jeito-capital-leads-67-5m-series-b-financing-for-cardiovascular-gene-therapy 2025-01-09T10:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jeito-capital-leads-67-5m-series-b-financing-for-cardiovascular-gene-therapy 2025-01-09T10:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/second-university-of-minnesota-study-shows-no-hydroxychloroquine-benefit-in-covid-19-fight 2025-01-09T10:45:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-university-of-minnesota-study-shows-no-hydroxychloroquine-benefit-in-covid-19-fight 2025-01-09T10:45:22+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-and-radiographic-evaluation-of-silver-diamine-fluoride-versus-mineral-trioxide-aggregate-in-indirect-pulp-capping 2025-01-09T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-and-radiographic-evaluation-of-silver-diamine-fluoride-versus-mineral-trioxide-aggregate-in-indirect-pulp-capping 2025-01-09T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/regional-chemotherapy-for-colorectal-liver-metastases-a-retrospective-study 2025-01-09T10:14:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regional-chemotherapy-for-colorectal-liver-metastases-a-retrospective-study 2025-01-09T10:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/jimmy-carter-s-melanoma-treatment-journey-revolutionizes-immunotherapy-acceptance-in-cancer-care 2025-01-09T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jimmy-carter-s-melanoma-treatment-journey-revolutionizes-immunotherapy-acceptance-in-cancer-care 2025-01-09T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-disease-market-set-to-surge-to-19-3b-by-2033-driven-by-novel-therapies 2025-01-09T09:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-disease-market-set-to-surge-to-19-3b-by-2033-driven-by-novel-therapies 2025-01-09T09:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/lyell-immunopharma-advances-next-generation-car-t-cell-therapy-impt-314-for-large-b-cell-lymphoma 2025-01-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyell-immunopharma-advances-next-generation-car-t-cell-therapy-impt-314-for-large-b-cell-lymphoma 2025-01-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-announces-positive-topline-results 2025-01-09T08:57:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-announces-positive-topline-results 2025-01-09T08:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/aardvark-therapeutics-strengthens-board-with-industry-leaders 2025-01-09T08:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aardvark-therapeutics-strengthens-board-with-industry-leaders 2025-01-09T08:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-prevention-program-shows-long-term-success-in-delaying-type-2-diabetes 2025-01-09T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diabetes-prevention-program-shows-long-term-success-in-delaying-type-2-diabetes 2025-01-09T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-palforzia-r-for-toddlers-with-peanut-allergy 2025-01-09T08:10:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-palforzia-r-for-toddlers-with-peanut-allergy 2025-01-09T08:10:12+00:00 hourly 0.9 https://trial.medpath.com/news/biotest-submits-biologics-license-application-for-fibrinogen-to-the-fda 2025-01-09T08:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotest-submits-biologics-license-application-for-fibrinogen-to-the-fda 2025-01-09T08:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-links-vitiligo-to-elevated-cardiovascular-disease-risk 2025-01-09T08:00:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-links-vitiligo-to-elevated-cardiovascular-disease-risk 2025-01-09T08:00:06+00:00 hourly 0.9 https://trial.medpath.com/news/elinzanetant-meets-all-primary-and-secondary-endpoints-in-phase-iii-study-oasis-4 2025-01-09T07:53:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elinzanetant-meets-all-primary-and-secondary-endpoints-in-phase-iii-study-oasis-4 2025-01-09T07:53:11+00:00 hourly 0.9 https://trial.medpath.com/news/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-clinical-trial 2025-01-09T07:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-toiva-clinical-trial 2025-01-09T07:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-to-present-at-j-p-morgan-s-43rd-annual-healthcare-conference 2025-01-09T07:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azafaros-to-present-at-j-p-morgan-s-43rd-annual-healthcare-conference 2025-01-09T07:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/evaluation-of-one-step-nucleic-acid-amplification-for-detection-of-lymph-node-metastases-in-endometrial-cancer 2025-01-09T07:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evaluation-of-one-step-nucleic-acid-amplification-for-detection-of-lymph-node-metastases-in-endometrial-cancer 2025-01-09T07:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-pharmaceuticals-announces-record-revenue-and-strong-financial-position-for-2024 2025-01-09T07:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-pharmaceuticals-announces-record-revenue-and-strong-financial-position-for-2024 2025-01-09T07:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-unique-psoriasis-care-perspectives-among-latine-patients-in-urban-healthcare-setting 2025-01-09T07:00:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-unique-psoriasis-care-perspectives-among-latine-patients-in-urban-healthcare-setting 2025-01-09T07:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/schizophrenia-market-forecasted-to-show-strong-growth-trajectory-by-2034 2025-01-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schizophrenia-market-forecasted-to-show-strong-growth-trajectory-by-2034 2025-01-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-celebrates-phase-3-win-in-prostate-cancer-with-viral-immunotherapy 2025-01-09T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-celebrates-phase-3-win-in-prostate-cancer-with-viral-immunotherapy 2025-01-09T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-liver-cancer-treatment-with-immunotherapy 2025-01-09T06:37:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-liver-cancer-treatment-with-immunotherapy 2025-01-09T06:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-to-announce-new-clinical-data-from-achieve-trial 2025-01-09T06:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-to-announce-new-clinical-data-from-achieve-trial 2025-01-09T06:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/life-sciences-industry-report-forecasts-glp-1s-ai-and-digital-health-to-drive-innovation-in-2025 2025-01-09T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/life-sciences-industry-report-forecasts-glp-1s-ai-and-digital-health-to-drive-innovation-in-2025 2025-01-09T06:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/ionic-liquids-enhance-skin-drug-delivery 2025-01-09T06:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionic-liquids-enhance-skin-drug-delivery 2025-01-09T06:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-pharmaceuticals-reports-progress-in-clinical-trials-and-strategic-growth-in-2024 2025-01-09T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-pharmaceuticals-reports-progress-in-clinical-trials-and-strategic-growth-in-2024 2025-01-09T06:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-sarclisa-subcutaneous-formulation-meets-co-primary-endpoints-in-iraklia-phase-3-study-for-multiple-myeloma 2025-01-09T06:03:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-sarclisa-subcutaneous-formulation-meets-co-primary-endpoints-in-iraklia-phase-3-study-for-multiple-myeloma 2025-01-09T06:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/geographic-and-financial-barriers-limit-access-to-revolutionary-cell-and-gene-therapies-mckesson-report-reveals 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geographic-and-financial-barriers-limit-access-to-revolutionary-cell-and-gene-therapies-mckesson-report-reveals 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gabapentin-doesn-t-increase-fall-risk-study-suggests 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gabapentin-doesn-t-increase-fall-risk-study-suggests 2025-01-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/anacardio-raises-sek-205-million-and-reports-positive-phase-1b-data-of-ac01 2025-01-09T05:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anacardio-raises-sek-205-million-and-reports-positive-phase-1b-data-of-ac01 2025-01-09T05:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioanalysis-emerges-as-critical-foundation-for-precision-medicine-development 2025-01-09T05:42:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioanalysis-emerges-as-critical-foundation-for-precision-medicine-development 2025-01-09T05:42:43+00:00 hourly 0.9 https://trial.medpath.com/news/bitterroot-bio-announces-positive-phase-1-study-results-for-brb-002-in-healthy-volunteers 2025-01-09T05:37:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bitterroot-bio-announces-positive-phase-1-study-results-for-brb-002-in-healthy-volunteers 2025-01-09T05:37:59+00:00 hourly 0.9 https://trial.medpath.com/news/vivacelle-bio-to-showcase-phase-3-treatment-for-shock-and-trauma-at-bio-partnering-jpm-week-2025 2025-01-09T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivacelle-bio-to-showcase-phase-3-treatment-for-shock-and-trauma-at-bio-partnering-jpm-week-2025 2025-01-09T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-critical-gaps-in-uk-s-pharma-doctor-payment-disclosure-system 2025-01-09T05:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-critical-gaps-in-uk-s-pharma-doctor-payment-disclosure-system 2025-01-09T05:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/historical-medical-mistrust-and-safety-concerns-drive-covid-19-vaccine-hesitancy-among-black-women-study-reveals 2025-01-09T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/historical-medical-mistrust-and-safety-concerns-drive-covid-19-vaccine-hesitancy-among-black-women-study-reveals 2025-01-09T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amd-enters-ai-drug-discovery-space-with-20m-investment-in-absci 2025-01-09T02:29:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amd-enters-ai-drug-discovery-space-with-20m-investment-in-absci 2025-01-09T02:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-firms-expand-solo-global-phase-iii-activity-including-us-sites 2025-01-09T02:01:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-firms-expand-solo-global-phase-iii-activity-including-us-sites 2025-01-09T02:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/racial-and-gender-microaggressions-during-pregnancy-linked-to-elevated-postpartum-blood-pressure 2025-01-09T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/racial-and-gender-microaggressions-during-pregnancy-linked-to-elevated-postpartum-blood-pressure 2025-01-09T02:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-astellas-pharma-s-revised-snda-for-izervay-in-geographic-atrophy-treatment 2025-01-09T01:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-astellas-pharma-s-revised-snda-for-izervay-in-geographic-atrophy-treatment 2025-01-09T01:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/seikagaku-s-pain-drug-may-need-more-tailored-indication-rems-for-approval 2025-01-09T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seikagaku-s-pain-drug-may-need-more-tailored-indication-rems-for-approval 2025-01-09T01:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-s-promising-tce-oncology-assets-earn-buy-rating-from-joseph-stringer 2025-01-09T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-s-promising-tce-oncology-assets-earn-buy-rating-from-joseph-stringer 2025-01-09T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-partners-with-transgene-to-test-opdivo-tg4010-vaccine-combo-in-pd-l1-low-nsclc 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-partners-with-transgene-to-test-opdivo-tg4010-vaccine-combo-in-pd-l1-low-nsclc 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccination-shows-strong-t-cell-response-in-multiple-myeloma-patients-on-lenalidomide-therapy 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-vaccination-shows-strong-t-cell-response-in-multiple-myeloma-patients-on-lenalidomide-therapy 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-and-lilly-s-lebrikizumab-shows-promise-for-long-term-atopic-dermatitis-management 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/almirall-and-lilly-s-lebrikizumab-shows-promise-for-long-term-atopic-dermatitis-management 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-clinical-trials-at-university-of-minnesota-offer-new-hope-for-glioblastoma-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-clinical-trials-at-university-of-minnesota-offer-new-hope-for-glioblastoma-patients 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/combining-pi3kg-inhibition-with-radiotherapy-enhances-tumor-control-in-pancreatic-cancer 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combining-pi3kg-inhibition-with-radiotherapy-enhances-tumor-control-in-pancreatic-cancer 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/genascence-s-gene-therapy-shows-promising-safety-profile-in-phase-1b-osteoarthritis-trial 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genascence-s-gene-therapy-shows-promising-safety-profile-in-phase-1b-osteoarthritis-trial 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-tuberculosis-treatment-new-antibiotic-btz-043-shows-promising-results 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-tuberculosis-treatment-new-antibiotic-btz-043-shows-promising-results 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/genascence-s-gene-therapy-shows-promising-safety-profile-in-phase-1b-osteoarthritis-trial 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genascence-s-gene-therapy-shows-promising-safety-profile-in-phase-1b-osteoarthritis-trial 2025-01-09T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-highlights-anticipated-2025-milestones-and-2024-key-accomplishments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-highlights-anticipated-2025-milestones-and-2024-key-accomplishments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-or-concurrent-atezolizumab-with-chemoradiation-for-locally-advanced-cervical-cancer 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-or-concurrent-atezolizumab-with-chemoradiation-for-locally-advanced-cervical-cancer 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-to-present-latest-clinical-data-of-hlx10-and-hlx22-at-2025-asco-gi 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-to-present-latest-clinical-data-of-hlx10-and-hlx22-at-2025-asco-gi 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-announces-breakthroughs-in-multiple-myeloma-and-ms-treatments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-announces-breakthroughs-in-multiple-myeloma-and-ms-treatments 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/europe-wide-study-aims-to-accelerate-depression-treatment-discovery 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/europe-wide-study-aims-to-accelerate-depression-treatment-discovery 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-sa-advances-in-gut-microbiome-driven-therapies-for-cancer-treatment 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-sa-advances-in-gut-microbiome-driven-therapies-for-cancer-treatment 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trisalus-life-sciences-announces-publication-of-pre-clinical-data-on-improved-delivery-of-embospheres-to-liver-tumors 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trisalus-life-sciences-announces-publication-of-pre-clinical-data-on-improved-delivery-of-embospheres-to-liver-tumors 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/prospective-validation-of-oracle-in-lung-adenocarcinoma-prognosis 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prospective-validation-of-oracle-in-lung-adenocarcinoma-prognosis 2025-01-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clearpoint-neuro-achieves-fda-de-novo-marketing-authorization-for-smartflow-cannula 2025-01-08T23:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearpoint-neuro-achieves-fda-de-novo-marketing-authorization-for-smartflow-cannula 2025-01-08T23:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/aerwave-completes-first-in-human-study-of-lung-denervation-technology 2025-01-08T23:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aerwave-completes-first-in-human-study-of-lung-denervation-technology 2025-01-08T23:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/jpmorgan-raises-vir-biotechnology-price-target-to-14 2025-01-08T22:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jpmorgan-raises-vir-biotechnology-price-target-to-14 2025-01-08T22:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-initiates-phase-2-trial-for-oral-vk2735-in-obesity-treatment 2025-01-08T22:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-initiates-phase-2-trial-for-oral-vk2735-in-obesity-treatment 2025-01-08T22:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/cognition-therapeutics-ceo-to-present-at-upcoming-healthcare-conferences 2025-01-08T22:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognition-therapeutics-ceo-to-present-at-upcoming-healthcare-conferences 2025-01-08T22:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/updates-on-ruxolitinib-combinations-for-mpns-from-ash-2024 2025-01-08T22:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updates-on-ruxolitinib-combinations-for-mpns-from-ash-2024 2025-01-08T22:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-advances-sma-treatment-apitegromab-towards-commercialization 2025-01-08T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-advances-sma-treatment-apitegromab-towards-commercialization 2025-01-08T21:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/zymeworks-announces-strategic-priorities-and-outlook-for-2025-and-2026 2025-01-08T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymeworks-announces-strategic-priorities-and-outlook-for-2025-and-2026 2025-01-08T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-health-pioneers-use-of-novel-pvad-system-in-cardiology 2025-01-08T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-health-pioneers-use-of-novel-pvad-system-in-cardiology 2025-01-08T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/c-reactive-protein-identified-as-key-biomarker-for-hidradenitis-suppurativa-treatment-efficacy 2025-01-08T21:00:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/c-reactive-protein-identified-as-key-biomarker-for-hidradenitis-suppurativa-treatment-efficacy 2025-01-08T21:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/tiziana-life-sciences-advances-in-immunomodulation-therapies-and-clinical-trials 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiziana-life-sciences-advances-in-immunomodulation-therapies-and-clinical-trials 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dx-vx-advances-ferritin-based-universal-coronavirus-vaccine-to-phase-2-trials-following-promising-phase-1-results 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dx-vx-advances-ferritin-based-universal-coronavirus-vaccine-to-phase-2-trials-following-promising-phase-1-results 2025-01-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/physiomics-project-and-cambridge-cognition-make-strides-in-medical-research 2025-01-08T20:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physiomics-project-and-cambridge-cognition-make-strides-in-medical-research 2025-01-08T20:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/tech-innovations-and-strategic-partnerships-highlight-ces-2025 2025-01-08T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tech-innovations-and-strategic-partnerships-highlight-ces-2025 2025-01-08T20:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/testing-the-progress-of-precision-prostate-cancer-screening 2025-01-08T20:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/testing-the-progress-of-precision-prostate-cancer-screening 2025-01-08T20:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/cofactor-genomics-inc-announces-ceo-transition-and-highlights-clinical-trial-successes 2025-01-08T20:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cofactor-genomics-inc-announces-ceo-transition-and-highlights-clinical-trial-successes 2025-01-08T20:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-xenotransplantation-genetically-modified-porcine-heart-transplanted-into-human 2025-01-08T19:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-xenotransplantation-genetically-modified-porcine-heart-transplanted-into-human 2025-01-08T19:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-halts-varipulse-pulsed-field-ablation-cases-in-the-us 2025-01-08T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-halts-varipulse-pulsed-field-ablation-cases-in-the-us 2025-01-08T19:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/disitamab-vedotin-and-toripalimab-show-promising-results-in-urothelial-carcinoma-treatment 2025-01-08T19:18:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disitamab-vedotin-and-toripalimab-show-promising-results-in-urothelial-carcinoma-treatment 2025-01-08T19:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/unc-breakthrough-research-on-food-allergy-drug-featured-in-national-geographic 2025-01-08T19:17:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unc-breakthrough-research-on-food-allergy-drug-featured-in-national-geographic 2025-01-08T19:17:53+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-addresses-market-rumors-and-updates-on-ht-001-clinical-trial-progress 2025-01-08T18:50:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-addresses-market-rumors-and-updates-on-ht-001-clinical-trial-progress 2025-01-08T18:50:47+00:00 hourly 0.9 https://trial.medpath.com/news/maat-pharma-announces-positive-topline-results-from-ares-study 2025-01-08T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maat-pharma-announces-positive-topline-results-from-ares-study 2025-01-08T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/eirion-reports-positive-results-in-topical-hair-loss-therapy-trial 2025-01-08T18:01:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eirion-reports-positive-results-in-topical-hair-loss-therapy-trial 2025-01-08T18:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/adcentrx-initiates-phase-1a-b-study-for-adrx-0405-targeting-steap1-in-advanced-solid-tumours 2025-01-08T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adcentrx-initiates-phase-1a-b-study-for-adrx-0405-targeting-steap1-in-advanced-solid-tumours 2025-01-08T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoag-family-cancer-institute-advances-glioblastoma-treatment-with-innovative-clinical-trials 2025-01-08T17:40:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoag-family-cancer-institute-advances-glioblastoma-treatment-with-innovative-clinical-trials 2025-01-08T17:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-sustained-5-weight-loss-to-establish-efficacy-of-new-antiobesity-medications 2025-01-08T17:40:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-sustained-5-weight-loss-to-establish-efficacy-of-new-antiobesity-medications 2025-01-08T17:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/catalyst-pharmaceuticals-secures-patent-settlement-with-teva-extending-firdapse-market-exclusivity-until-2035 2025-01-08T17:35:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalyst-pharmaceuticals-secures-patent-settlement-with-teva-extending-firdapse-market-exclusivity-until-2035 2025-01-08T17:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-offers-hope-for-type-2-diabetes-patients-struggling-with-weight-loss 2025-01-08T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-offers-hope-for-type-2-diabetes-patients-struggling-with-weight-loss 2025-01-08T17:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/tenvie-raises-200m-for-brain-drug-r-d-sana-spikes-on-single-patient-s-results 2025-01-08T16:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenvie-raises-200m-for-brain-drug-r-d-sana-spikes-on-single-patient-s-results 2025-01-08T16:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-announces-acquisition-agreement-for-bolt-medical 2025-01-08T16:43:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-announces-acquisition-agreement-for-bolt-medical 2025-01-08T16:43:41+00:00 hourly 0.9 https://trial.medpath.com/news/curevo-vaccine-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curevo-vaccine-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-stock-soars-on-prostate-cancer-trial-data 2025-01-08T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-stock-soars-on-prostate-cancer-trial-data 2025-01-08T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/indaptus-therapeutics-highlights-2024-achievements-and-2025-outlook 2025-01-08T16:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indaptus-therapeutics-highlights-2024-achievements-and-2025-outlook 2025-01-08T16:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/suven-life-sciences-shares-surge-10-following-phase-1-clinical-trial-announcement 2025-01-08T15:42:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/suven-life-sciences-shares-surge-10-following-phase-1-clinical-trial-announcement 2025-01-08T15:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-stock-receives-buy-rating-after-promising-phase-1-diabetes-treatment-results 2025-01-08T15:41:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-stock-receives-buy-rating-after-promising-phase-1-diabetes-treatment-results 2025-01-08T15:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-inc-achieves-key-milestone-in-phase-3-study-of-ameluz-for-superficial-basal-cell-carcinoma-treatment 2025-01-08T15:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-inc-achieves-key-milestone-in-phase-3-study-of-ameluz-for-superficial-basal-cell-carcinoma-treatment 2025-01-08T15:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-breakthrough-in-type-1-diabetes-treatment 2025-01-08T15:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-breakthrough-in-type-1-diabetes-treatment 2025-01-08T15:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/geron-stock-rallies-more-than-60-in-a-year-here-s-why 2025-01-08T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-stock-rallies-more-than-60-in-a-year-here-s-why 2025-01-08T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-reports-positive-phase-i-trial-results-for-glp-1ra-in-treating-hypoglycaemia 2025-01-08T15:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-reports-positive-phase-i-trial-results-for-glp-1ra-in-treating-hypoglycaemia 2025-01-08T15:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/updates-on-clinical-trials-funding-and-shelved-projects-in-ophthalmology 2025-01-08T15:20:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updates-on-clinical-trials-funding-and-shelved-projects-in-ophthalmology 2025-01-08T15:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/moma-therapeutics-advances-in-precision-medicine-with-new-parp1-inhibitor-and-clinical-updates 2025-01-08T14:54:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moma-therapeutics-advances-in-precision-medicine-with-new-parp1-inhibitor-and-clinical-updates 2025-01-08T14:54:04+00:00 hourly 0.9 https://trial.medpath.com/news/5-questions-novo-nordisk-must-answer-to-drive-its-stock-higher 2025-01-08T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/5-questions-novo-nordisk-must-answer-to-drive-its-stock-higher 2025-01-08T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-therapeutics-initiates-phase-2-trial-for-abx-002-in-bipolar-depression-treatment 2025-01-08T14:38:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autobahn-therapeutics-initiates-phase-2-trial-for-abx-002-in-bipolar-depression-treatment 2025-01-08T14:38:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cnp-104-for-primary-biliary-cholangitis 2025-01-08T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-cnp-104-for-primary-biliary-cholangitis 2025-01-08T14:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-posdinemab-granted-fda-fast-track-designation-for-alzheimer-s-treatment 2025-01-08T14:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-posdinemab-granted-fda-fast-track-designation-for-alzheimer-s-treatment 2025-01-08T14:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/lb-pharmaceuticals-reveals-phase-2-schizophrenia-data 2025-01-08T14:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lb-pharmaceuticals-reveals-phase-2-schizophrenia-data 2025-01-08T14:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/anokion-announces-positive-symptom-data-from-its-phase-2-trial-evaluating-kan-101-for-celiac-disease 2025-01-08T14:30:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anokion-announces-positive-symptom-data-from-its-phase-2-trial-evaluating-kan-101-for-celiac-disease 2025-01-08T14:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/quanta-receives-fda-ind-clearance-for-qtx3544-and-advances-kras-inhibitor-pipeline 2025-01-08T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanta-receives-fda-ind-clearance-for-qtx3544-and-advances-kras-inhibitor-pipeline 2025-01-08T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/community-engagement-methods-in-fm-tips-trial-to-be-discussed-at-pct-grand-rounds 2025-01-08T14:25:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/community-engagement-methods-in-fm-tips-trial-to-be-discussed-at-pct-grand-rounds 2025-01-08T14:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/inpatient-treatment-of-suicidality-a-systematic-review-of-clinical-trials 2025-01-08T14:20:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inpatient-treatment-of-suicidality-a-systematic-review-of-clinical-trials 2025-01-08T14:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-advances-cancer-drug-trials-with-key-2025-milestones-in-sight 2025-01-08T14:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-advances-cancer-drug-trials-with-key-2025-milestones-in-sight 2025-01-08T14:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-biosciences-accelerates-path-to-first-drug-approval-and-expands-leadership-for-2025 2025-01-08T14:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidity-biosciences-accelerates-path-to-first-drug-approval-and-expands-leadership-for-2025 2025-01-08T14:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-decide-on-agios-request-for-expanded-approval-of-pyrukynd-in-thalassemia-by-september-7 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-decide-on-agios-request-for-expanded-approval-of-pyrukynd-in-thalassemia-by-september-7 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-oncology-to-present-real-world-data-on-colorectal-cancer-treatments-at-asco-gi-2025 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-oncology-to-present-real-world-data-on-colorectal-cancer-treatments-at-asco-gi-2025 2025-01-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-s-calma-trial-triples-alzheimer-s-patient-recruitment-with-ai-powered-strategy 2025-01-08T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-s-calma-trial-triples-alzheimer-s-patient-recruitment-with-ai-powered-strategy 2025-01-08T13:55:48+00:00 hourly 0.9 https://trial.medpath.com/news/bexion-pharmaceuticals-to-present-bxq-350-study-findings-at-asco-gi-2025 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bexion-pharmaceuticals-to-present-bxq-350-study-findings-at-asco-gi-2025 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/foresight-diagnostics-sets-strategic-goals-for-2025-following-a-year-of-significant-achievements 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresight-diagnostics-sets-strategic-goals-for-2025-following-a-year-of-significant-achievements 2025-01-08T13:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-updates-in-second-line-therapies-for-lr-mds 2025-01-08T13:40:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-updates-in-second-line-therapies-for-lr-mds 2025-01-08T13:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-and-fresenius-kabi-canada-receive-health-canada-s-approval-for-fyb202-otulfi 2025-01-08T13:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-and-fresenius-kabi-canada-receive-health-canada-s-approval-for-fyb202-otulfi 2025-01-08T13:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-reports-encouraging-phase-1-data-for-two-cancer-drug-candidates 2025-01-08T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-reports-encouraging-phase-1-data-for-two-cancer-drug-candidates 2025-01-08T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-oncology-pipeline-with-new-drug-candidates-and-clinical-trials 2025-01-08T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-therapeutics-advances-oncology-pipeline-with-new-drug-candidates-and-clinical-trials 2025-01-08T13:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/vigeneron-receives-fda-rare-pediatric-disease-designation-for-vg901-and-advances-in-phase-1b-retinitis-pigmentosa-trial 2025-01-08T13:24:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vigeneron-receives-fda-rare-pediatric-disease-designation-for-vg901-and-advances-in-phase-1b-retinitis-pigmentosa-trial 2025-01-08T13:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-highlights-2024-achievements-and-future-plans-in-annual-shareholder-letter 2025-01-08T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-highlights-2024-achievements-and-future-plans-in-annual-shareholder-letter 2025-01-08T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/replimune-advances-rp2-development-program-with-clinical-trials-for-melanoma-and-liver-cancer 2025-01-08T13:12:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/replimune-advances-rp2-development-program-with-clinical-trials-for-melanoma-and-liver-cancer 2025-01-08T13:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-and-challenges-in-cancer-care-and-treatment-planning 2025-01-08T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-and-challenges-in-cancer-care-and-treatment-planning 2025-01-08T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-receives-fda-breakthrough-therapy-designation-for-tividenofusp-alfa-in-hunter-syndrome-treatment 2025-01-08T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-receives-fda-breakthrough-therapy-designation-for-tividenofusp-alfa-in-hunter-syndrome-treatment 2025-01-08T13:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/viva-biotech-s-portfolio-companies-showcase-significant-r-d-progress 2025-01-08T13:01:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viva-biotech-s-portfolio-companies-showcase-significant-r-d-progress 2025-01-08T13:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/tinivo-2-trial-highlights-challenges-in-ici-retreatment-for-advanced-rcc 2025-01-08T13:00:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tinivo-2-trial-highlights-challenges-in-ici-retreatment-for-advanced-rcc 2025-01-08T13:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-spinout-secures-200m-in-funding 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-spinout-secures-200m-in-funding 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/asher-bio-and-amgen-collaborate-on-clinical-trial-for-es-sclc-treatment 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asher-bio-and-amgen-collaborate-on-clinical-trial-for-es-sclc-treatment 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-to-present-corporate-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-to-present-corporate-update-at-43rd-annual-j-p-morgan-healthcare-conference 2025-01-08T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-announces-key-milestones-and-updates-for-solnerstotug-sns-101 2025-01-08T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensei-biotherapeutics-announces-key-milestones-and-updates-for-solnerstotug-sns-101 2025-01-08T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-life-sciences-reaches-critical-milestone-in-orca-ol-clinical-trial-for-cytisinicline 2025-01-08T12:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-life-sciences-reaches-critical-milestone-in-orca-ol-clinical-trial-for-cytisinicline 2025-01-08T12:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/edap-announces-first-pancreatic-cancer-patient-treated-with-proprietary-hifu-technology 2025-01-08T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edap-announces-first-pancreatic-cancer-patient-treated-with-proprietary-hifu-technology 2025-01-08T12:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-targeting-cs-aki 2025-01-08T12:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arch-biopartners-receives-ethics-approval-for-phase-ii-trial-of-lsalt-peptide-targeting-cs-aki 2025-01-08T12:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/biodesix-s-nodify-cdt-blood-test-shows-promise-in-lung-cancer-detection-study 2025-01-08T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodesix-s-nodify-cdt-blood-test-shows-promise-in-lung-cancer-detection-study 2025-01-08T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-s-invikafusp-alfa-receives-fda-fast-track-designation-for-advanced-colorectal-cancer-treatment 2025-01-08T12:27:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-s-invikafusp-alfa-receives-fda-fast-track-designation-for-advanced-colorectal-cancer-treatment 2025-01-08T12:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/compugen-advances-com503-into-phase-1-clinical-trial-for-advanced-solid-tumors 2025-01-08T12:27:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compugen-advances-com503-into-phase-1-clinical-trial-for-advanced-solid-tumors 2025-01-08T12:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-projects-continued-growth-with-2025-financial-guidance-and-strategic-expansions 2025-01-08T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamada-projects-continued-growth-with-2025-financial-guidance-and-strategic-expansions 2025-01-08T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-receives-buy-rating-based-on-strong-phase-3-trial-design-and-early-results 2025-01-08T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-receives-buy-rating-based-on-strong-phase-3-trial-design-and-early-results 2025-01-08T12:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/equivalence-confirmed-ct-p41-paves-the-way-for-affordable-osteoporosis-care 2025-01-08T12:12:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/equivalence-confirmed-ct-p41-paves-the-way-for-affordable-osteoporosis-care 2025-01-08T12:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/biostem-technologies-launches-clinical-trial-to-demonstrate-therapeutic-benefits-of-bioretain-technology-in-treating-diabetic-foot-ulcers 2025-01-08T12:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostem-technologies-launches-clinical-trial-to-demonstrate-therapeutic-benefits-of-bioretain-technology-in-treating-diabetic-foot-ulcers 2025-01-08T12:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-initiates-three-new-clinical-trials-for-sonelokimab-in-dermatology-and-rheumatology 2025-01-08T12:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-initiates-three-new-clinical-trials-for-sonelokimab-in-dermatology-and-rheumatology 2025-01-08T12:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-clinical-alert-system-shows-10x-improvement-in-suicide-risk-screening-rates 2025-01-08T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-clinical-alert-system-shows-10x-improvement-in-suicide-risk-screening-rates 2025-01-08T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/lb-pharmaceuticals-announces-positive-topline-results-for-lb-102-in-schizophrenia-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lb-pharmaceuticals-announces-positive-topline-results-for-lb-102-in-schizophrenia-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-injectable-antipsychotics-show-promise-in-adolescent-bipolar-mania-management 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-injectable-antipsychotics-show-promise-in-adolescent-bipolar-mania-management 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-revolutionary-breakthrough-in-type-1-diabetes-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-revolutionary-breakthrough-in-type-1-diabetes-treatment 2025-01-08T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-advances-targeted-cancer-therapy-with-tamp-platform 2025-01-08T11:29:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-advances-targeted-cancer-therapy-with-tamp-platform 2025-01-08T11:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/moonlake-immunotherapeutics-affirmed-with-buy-rating-for-strategic-clinical-expansion 2025-01-08T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlake-immunotherapeutics-affirmed-with-buy-rating-for-strategic-clinical-expansion 2025-01-08T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/nephrology-month-in-review-december-2024 2025-01-08T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nephrology-month-in-review-december-2024 2025-01-08T11:00:00+00:00 hourly 0.9